0001376339-16-000203.txt : 20160802 0001376339-16-000203.hdr.sgml : 20160802 20160802163725 ACCESSION NUMBER: 0001376339-16-000203 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160802 DATE AS OF CHANGE: 20160802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 900300868 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 161800995 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: 678-384-6720 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-Q 1 mdxg-2016630x10xq.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended June 30, 2016
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________to______________________

Commission file number 001-35887

MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)

Florida
 
26-2792552
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification Number)
1775 West Oak Commons Ct NE
Marietta, GA
 
30062
(Address of principal executive offices)
 
(Zip Code)

(770) 651-9100
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x     No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x
Accelerated filer ¨
Non-accelerated filer ¨
(Do not check if a smaller reporting company)
Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No x
 
As of July 15, 2016, there were 110,042,283 shares of the registrant’s common stock outstanding.



Table of Contents
 
Part I     FINANCIAL INFORMATION
 
Item 1
Condensed Consolidated Financial Statements
 
 
Condensed Consolidated Balance Sheets (unaudited) June 30, 2016 and December 31, 2015

 
Condensed Consolidated Statements of Operations (unaudited) Three and Six Months Ended June 30, 2016 and 2015

 
Condensed Consolidated Statements of Stockholders' Equity (unaudited) for Six Months Ended June 30, 2016

 
Condensed Consolidated Statements of Cash Flows (unaudited) Six Months Ended June 30, 2016 and 2015

 
Notes to the Unaudited Condensed Consolidated Financial Statements Three and Six Months Ended June 30, 2016 and 2015
8

Item 2
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3
Quantitative and Qualitative Disclosures About Market Risk

Item 4
Controls and Procedures

Part II   OTHER INFORMATION
Item 1
Legal Proceedings

Item 1A
Risk Factors

Item 2
Unregistered Sales of Equity Securities and Use of Proceeds

Item 3
Defaults upon Senior Securities

Item 4
Mine Safety Disclosures

Item 5
Other Information

Item 6
Exhibits

Signatures
 


2


Forward-Looking Statements
 
This Form 10-Q and certain information incorporated herein by reference contain forward-looking statements and information within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934.  This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of our products by the market, and management’s plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “believe,” “expect,” “expectation,” “anticipate,” “estimate,” “intend,” “seeks,” “plan,” “project,” “continue,” “predict,” “will,” “should,” and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference.  These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.
Our actual results may differ materially from those expressed or implied in these forward-looking statements.  Factors that may cause such a difference include, but are not limited to, those discussed in Part II, Item 1A, “Risk Factors,” below and in our most recent Annual Report on Form 10-K, as well as other reports we file with the SEC.  Except as expressly required by the federal securities laws, we undertake no obligation to update any such factors, or to publicly announce the results of, or changes to any of the forward-looking statements contained herein to reflect future events, developments, changed circumstances, or for any other reason.
As used herein, the terms “MiMedx,” “the Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.



3



Part I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
 
June 30, 2016
(unaudited)
 
December 31, 2015
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
23,803

 
$
28,486

Short term investments
—

 
3,000

Accounts receivable, net
54,861

 
53,755

Inventory, net
17,207

 
7,460

Prepaid expenses and other current assets
5,970

 
3,609

Total current assets
101,841

 
96,310

Property and equipment, net of accumulated depreciation
13,049

 
9,475

Goodwill
26,951

 
4,040

Intangible assets, net of accumulated amortization
27,693

 
10,763

Deferred tax asset, net
7,077

 
14,838

Deferred financing costs and other assets
444

 
487

Total assets
$
177,055

 
$
135,913

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
9,678

 
$
6,633

Accrued compensation
10,245

 
15,034

Accrued expenses
6,988

 
4,644

Current portion of earn out liability
9,642

 
—

Other current liabilities
1,985

 
466

Total current liabilities
38,538

 
26,777

Earn out liability
15,978

 
—

Other liabilities
934

 
1,148

Total liabilities
55,450

 
27,925

Commitments and contingencies (Note 14)


 


Stockholders' equity:
 
 
 
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding
—

 
—

Common stock; $.001 par value; 150,000,000 shares authorized;
110,025,697 issued and 110,022,283 outstanding at June 30, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015
110

 
109

Additional paid-in capital
156,457

 
163,133

Treasury stock at cost:
3,414 shares at June 30, 2016 and 2,105,945 shares at December 31, 2015
(4
)
 
(17,124
)
Accumulated deficit
(34,958
)
 
(38,130
)
Total stockholders' equity
121,605

 
107,988

Total liabilities and stockholders' equity
$
177,055

 
$
135,913

See notes to condensed consolidated financial statements

4


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015

 
 
 
 
 
 
 
Net sales
$
57,342

 
$
45,679

 
$
110,710

 
$
86,446

Cost of sales
7,394

 
5,089

 
15,341

 
10,237

Gross margin
49,948

 
40,590

 
95,369

 
76,209

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Research and development expenses
3,168

 
2,054

 
5,664

 
3,885

Selling, general and administrative expenses
42,772

 
32,651

 
83,420

 
61,960

Amortization of intangible assets
447

 
233

 
1,257

 
465

Operating income
3,561

 
5,652

 
5,028

 
9,899

 
 
 
 
 
 
 
 
Other income (expense), net
 
 
 
 
 
 
 
Interest income (expense), net
(111
)
 
1

 
(167
)
 
(13
)
 
 
 
 
 
 
 
 
Income before income tax provision
3,450

 
5,653

 
4,861

 
9,886

Income tax provision
(1,475
)
 
(223
)
 
(1,689
)
 
(369
)
 
 
 
 
 
 
 
 
Net income
$
1,975

 
$
5,430

 
$
3,172

 
$
9,517

 
 
 
 
 
 
 
 
Net income per common share - basic
$
0.02

 
$
0.05

 
$
0.03

 
$
0.09

 
 
 
 
 
 
 
 
Net income per common share - diluted
$
0.02

 
$
0.05

 
$
0.03

 
$
0.08

 
 
 
 
 
 
 
 
Weighted average shares outstanding - basic
106,191,932

 
106,211,120

 
105,873,727

 
106,013,752

 
 
 
 
 
 
 
 
Weighted average shares outstanding - diluted
112,148,415

 
114,186,329

 
112,095,051

 
113,892,087

See notes to condensed consolidated financial statements

5



MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands, except share data)
(unaudited)



 
 
Common Stock Issued

Treasury Stock
 
 
 
 
Shares
Amount
Additional Paid - in Capital
Shares
Amount
Accumulated Deficit
Total
Balance December 31, 2015
 
109,467,416

$
109

$
163,133

2,105,945

$
(17,124
)
$
(38,130
)
$
107,988

Share-based compensation expense
 
—

—

9,124

—

—

—

9,124

Exercise of stock options
 
223,928

—

(2,745
)
(580,113
)
4,761

—

2,016

Issuance of restricted stock
 
334,353

1

(13,422
)
(1,660,079
)
13,421

—

—

Restricted stock shares cancelled/forfeited
 
—

—

825

102,230

(825
)
—

—

Shares issued for services performed
 

—

4

(20,406
)
169

—

173

Stock repurchase
 
—

—

—

415,252

(3,530
)
—

(3,530
)
Shares repurchased for tax withholding
 
—

—

—

81,594

(684
)
 
(684
)
Shares issued in conjunction with acquisition
 
—

—

(462
)
(441,009
)
3,808

 
3,346

Net income
 
—

—

—

—

—

3,172

3,172

Balance June 30, 2016
 
110,025,697

$
110

$
156,457

3,414

$
(4
)
$
(34,958
)
$
121,605


See notes to condensed consolidated financial statements

6


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
Six Months Ended June 30,
 
2016
 
2015
Cash flows from operating activities:
 
 
 
Net income
$
3,172

 
$
9,517

Adjustments to reconcile net income to net cash from operating activities:
 
 
 
Depreciation
1,555

 
776

Amortization of intangible assets
1,257

 
465

Amortization of inventory fair value step-up
1,224

 
—

Amortization of deferred financing costs
91

 
—

Share-based compensation
9,124

 
8,186

Increase (decrease) in cash, net of effects of acquisition, resulting from changes in:
 
 
 
  Accounts receivable
894

 
(12,776
)
  Inventory
(2,245
)
 
1,274

  Prepaid expenses and other current assets
(1,781
)
 
(1,106
)
  Other assets
(264
)
 
(26
)
  Accounts payable
(5,597
)
 
2,060

  Accrued compensation
(4,789
)
 
(1,862
)
  Accrued expenses
2,344

 
1,221

  Other liabilities
1,318

 
(586
)
Net cash flows from operating activities
6,303

 
7,143

 
 
 
 
Cash flows from investing activities:
 
 
 
 Purchases of equipment
(3,755
)
 
(2,513
)
 Purchase of Stability Inc., net of cash acquired
(7,631
)
 
—

 Fixed maturity securities redemption
3,000

 
1,750

 Patent application costs
(327
)
 
(402
)
Net cash flows from investing activities
(8,713
)
 
(1,165
)
 
 
 
 
Cash flows from financing activities:
 
 
 
 Proceeds from exercise of stock options
2,016

 
2,741

 Stock repurchase under repurchase plan
(3,530
)
 
(16,641
)
 Stock repurchase for tax withholdings on vesting of restricted stock
(684
)
 
—

 Deferred financing costs
(61
)
 
—

 Payments under capital lease obligations
(14
)
 
(59
)
Net cash flows from financing activities
(2,273
)
 
(13,959
)
 
 
 
 
Net change in cash
(4,683
)
 
(7,981
)
 
 
 
 
Cash and cash equivalents, beginning of period
28,486

 
46,582

Cash and cash equivalents, end of period
$
23,803

 
$
38,601

See notes to condensed consolidated financial statements

7


MIMEDX GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2016 AND 2015
1.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the six months ended June 30, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology, CollaFix™, which the Company has yet to commercialize. Through the recent acquisition of Stability Inc., our newest proprietary platforms include Physio®, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn™, a skin product for burns.
2.
Significant Accounting Policies
Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2015, for a description of all significant accounting policies. 
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of June 30, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately $800,000, which is comprised of approximately $2.0 million as of the date of the acquisition less amortization of approximately $1.2 million during the six months ended June 30, 2016. Please see Note 4 contained herein.



8


Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $327,000 of patent costs during the first six months of 2016. The Company capitalized approximately $402,000 of patent costs during the first six months of 2015.
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and
not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with
Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when
companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting
periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company
is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, 'Balance Sheet Classification of Deferred Taxes'. ASU 2015-17
simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the
balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,
and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption
is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify
reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.

In February 2016, the FASB issued ASU No. 2016-02, 'Leases (Topic 842)'. The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is

9


intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.

All other ASUs issued and not yet effective for the six months ended June 30, 2016, and through the date of this report,
were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial
position or results of operations.

3.
Liquidity and Management’s Plans
As of June 30, 2016, the Company had approximately $23,803,000 of cash and cash equivalents.  The Company reported total current assets of approximately $101,841,000 and current liabilities of approximately $38,538,000 as of June 30, 2016.  The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.

4. Acquisition of Stability Inc.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human
tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare
industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for
$6,000,000 cash, $3,346,000 in stock, represented by 441,009 shares of our common stock, and assumed debt of $1,771,000. Additional one time costs incurred in connection with the transaction totaled $851,000 and are included withing selling, general and administrative expenses on the condensed consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of June 30, 2016, the contingent consideration was valued at $25,620,000 and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability.

The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the
contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument,
other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number
of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or
predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs
associated with the combination. The actual purchase price has been preliminarily allocated as of June 30, 2016 (in
thousands) and is subject to change:


10


Cash paid at closing
 
$
6,000

Working capital adjustment
 
(480
)
Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn-out
 
25,620

Total fair value of purchase price
 
$
36,257

 
 
 
Net assets acquired:
 

Debt-free working capital
 
$
2,179

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(8,268
)
Subtotal
 
(4,515
)
Intangible assets:
 
 
Customer relationships
 
6,090

Patents and know-how
 
9,170

Trade names and trademarks
 
830

Non compete agreements
 
1,080

Licenses and permits
 
690

Subtotal
 
17,860

Goodwill
 
22,912

Total Assets Purchased
 
$
36,257

 
 
 
Working capital and other assets were composed of the following (in thousands):
 
 
Working capital
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
8,725

Accounts payable and accrued expenses
 
(8,815
)
Debt-free working capital
 
$
2,179

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of Credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
408

 
 

Other assets:
 
 
Other long term assets
 
$
199


The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - Business Combinations.
The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is
recorded at fair value on the acquisition date and will be remeasured quarterly until purchase accounting is completed based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income

11


valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization.The intangible assets were assigned the following lives for amortization purposes:

 
 
Estimated useful life (in years)
Intangible asset:
 
 
Customer relationships
 
12
Patents and know-how
 
20
Trade name and Trademarks
 
Indefinite
Non compete agreements
 
4
Licenses and permits
 
2

Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value.
Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in
the transaction and is preliminary as of June 30, 2016 and is subject to change. Goodwill is tested for impairment on an annual basis as definedby FASB Topic 350 - "Intangibles - Goodwill and Other".

The following unaudited pro forma summary financial information presents the consolidated results of operations as if the
acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport
to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative
of the results that may occur in the future.

Unaudited pro forma information for the three and six months ended June 30, 2016 and 2015 (in thousands) is as follows:

 
 
Three months ended June 30,
 
Six months ended June 30,
 
 
2016
2015
 
2016
2015
Revenue
 
$
57,342

$
50,492

 
$
111,258

$
96,413

 
 
 
 
 
 
 
Net income
 
$
2,057

$
4,919

 
$
3,668

$
7,975

 
 
 
 
 
 
 
Income per share, fully diluted
 
$
0.02

$
0.04

 
$
0.03

$
0.07


The 2016 supplemental pro forma earnings were adjusted to exclude $851,000 of acquisition-related legal, audit and other
costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include $787,000 of amortization costs related to
recorded intangible assets with defined useful lives, and $1,224,000 of inventory step-up charges as a result of the acquisition
for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include 441,009 shares issued as part of the purchase price and assumed to be issued on January 1, 2015.


5. Short Term Investments
Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015.

6. Inventories
Inventories consisted of the following items as of June 30, 2016, and December 31, 2015 (in thousands):

12


 
June 30, 2016
 
December 31, 2015
Raw materials
$
1,154

 
$
602

Work in process
5,888

 
3,850

Finished goods
11,945

 
3,405

 Inventory, gross
18,987

 
7,857

Reserve for obsolescence
(1,780
)
 
(397
)
 Inventory, net
$
17,207

 
$
7,460


7.
Property and Equipment 
Property and equipment consist of the following as of June 30, 2016, and December 31, 2015 (in thousands):
 
June 30,
2016
 
December 31,
2015
Leasehold improvements
$
3,245

 
$
2,684

Lab and clean room equipment
8,196

 
4,564

Furniture and office equipment
6,167

 
4,577

Construction in progress
2,169

 
2,629

   Property and equipment, gross
19,777

 
14,454

Less accumulated depreciation
(6,728
)
 
(4,979
)
   Property and equipment, net
$
13,049

 
$
9,475

Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $72,000 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately 3% to 12% with maturity dates from September 2016 to January 2018.
Also included is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
Depreciation expense for the six months ended June 30, 2016 and 2015, was approximately $1,555,000 and $776,000, respectively, and approximately $821,000 and $422,000 for the three months ended June 30, 2016 and 2015, respectively.

8.
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
June 30, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (d)
7 years
 
$
1,699

 
$
1,009

Patents & Know How (b) (d)
19 years
 
17,176

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
9,851

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
1,838

 
1,008

Non-compete agreements (d)
4 years
 
1,080

 
—

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
2,146

 
1,823

Total
 
 
33,815

 
15,627

Less Accumulated amortization and impairment charges
 
 
(6,122
)
 
(4,864
)
Net
 
 
$
27,693

 
$
10,763


13


(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the six months ended June 30, 2016, approximately $4,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents & Know - How of $9,170,000, Customer Relationships of $6,090,000, Non - compete agreements of$1,080,000, Tradenames & Trademarks of $830,000 and Licenses of $690,000.
Amortization expense for the six months ended June 30, 2016 and 2015, was approximately $1,257,000 and $465,000, respectively, and $447,000 and $233,000 for three months ended June 30, 2016 and 2015, respectively.
Expected future amortization of intangible assets as of June 30, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
1,259

2017
2,427

2018
2,072

2019
2,072

2020
1,802

Thereafter
16,223

 
$
25,855

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after June 30, 2016.

9. Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain
lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving
credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to
$50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be
exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and
conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%.
Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs
are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary
representations, warranties, covenants, and events of default. As of June 30, 2016, there were no outstanding revolving loans
under the credit facility.






14


10. Net Income (Loss) Per Share
Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Net income
$
1,975

 
$
5,430

 
$
3,172

 
$
9,517

Denominator for basic earnings per share - weighted average shares
106,191,932

 
106,211,120

 
105,873,727

 
106,013,752

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
5,956,483

 
7,975,209

 
6,221,324

 
7,878,335

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,148,415

 
114,186,329

 
112,095,051

 
113,892,087

Income per common share - basic
$
0.02

 
$
0.05

 
$
0.03

 
$
0.09

Income per common share - diluted
$
0.02

 
$
0.05


$
0.03


$
0.08

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Outstanding Stock Options
5,644,128

 
7,411,271

 
5,805,870

 
7,393,698

Outstanding Warrants
—

 
37,909

 
—

 
37,708

Restricted Stock Awards
312,355

 
526,029

 
415,454

 
446,929

 
5,956,483

 
7,975,209

 
6,221,324

 
7,878,335



11. Equity
Stock Incentive Plans 
The Company has four share-based compensation plans: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016, the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2016 Plan to make future grants.

15


Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(804,041
)
 
$
2.51

 
 
 
 
Unvested options forfeited
(79,810
)
 
$
6.44

 
 
 
 
Vested options expired
(29,191
)
 
$
6.44

 
 
 
 

Outstanding at June 30, 2016
13,106,587

 
$
3.67

 
6.0
 
$
56,844,050

Vested at June 30, 2016
11,710,880

 
$
3.27

 
5.8
 
$
55,362,178

Vested or expected to vest at June 30, 2016 (a)
13,047,941

 
$
3.66

 
6.0
 
$
56,809,041

(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the six months ended June 30, 2016, was approximately $4,937,922. 
Following is a summary of stock options outstanding and exercisable at June 30, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
2.9
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,420,470

 
5.2
 
1.19

 
4,420,470

 
1.19

$1.40 - $2.45
1,458,424

 
4.4
 
1.92

 
1,458,424

 
1.92

$2.66 - $3.99
889,430

 
6.3
 
3.06

 
889,430

 
3.06

$4.19 - $6.38
3,310,253

 
6.9
 
5.36

 
2,898,133

 
5.28

$6.45 - $9.78
2,479,415

 
7.6
 
7.29

 
1,586,502

 
7.23

$9.90- $10.99
107,166

 
8.4
 
10.43

 
36,492

 
10.44

 
13,106,587

 
6.0
 
$
3.67

 
11,730,880

 
$
3.27

 
Total unrecognized compensation expense related to granted stock options at June 30, 2016, was approximately $3,283,152 and will be charged to expense ratably through May 2018. 
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:

16


 
Six Months Ended June 30,
 
2016
 
2015
Expected volatility
n/a
 
54.4 - 58.1 %

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 
—

Risk-free interest rate
n/a
 
1.51% - 1.68%

There were no options granted during the six months ended June 30, 2016.
Restricted Stock Awards                                                    
Activity with respect to restricted stock awards is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
2,014,838

 
8.04
Vested
(825,595
)
 
8.63
Forfeited
(102,230
)
 
8.85

Unvested at June 30, 2016
3,700,280

 
$8.66
As of June 30, 2016, there was approximately $24,939,716 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.1 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at June 30, 2016.
For the three and six months ended June 30, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Cost of sales
$
95

 
$
90

 
$
190

 
$
184

Research and development
155

 
203

 
360

 
389

Selling, general and administrative
4,253

 
3,962

 
8,574

 
7,613

 
$
4,503

 
$
4,255

 
$
9,124

 
$
8,186

Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the six months ended June 30, 2016, the Company purchased 415,252 shares of its common stock for a purchase price of approximately $3,518,000 before brokerage commissions of approximately $12,000. As of June 30, 2016, the Company had approximately $10,756,000 of availability remaining under the repurchase program.
Additionally, for the six months ended June 30, 2016, the Company reissued 2,599,377 shares from the Treasury for restricted stock grants and stock option exercises, net of forfeitures, and as partial consideration to the shareholders of Stability, with an aggregate carrying value of approximately $21,334,000.


17


12. Income taxes 

The effective tax rates for continuing operations of 34.7% and 3.7% for the six months ended June 30, 2016 and June 30, 2015, respectively, were determined using an estimated annual effective tax rate and include, in 2016, the impact of a discrete item of approximately $350,000. The effective tax rate for the 2016 period increased approximately 31% when compared to the same period of 2015, primarily due to the $15.4 million valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the six months ended June 30, 2015, did not include the expense of the current period U.S. taxable income. As of the end of June 2016, the projected annual effective tax rate for 2016 is 42.2%.

13. Supplemental disclosure of cash flow and non-cash investing and financing activities:
    
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Six Months Ended June 30,
 
2016
 
2015
Cash paid for interest
$
76

 
$
29

Income taxes paid
631

 
874

Stock issuance of 441,009 shares in connection with acquisition
3,346

 
—

Retirement of fixed assets
—

 
308

Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively
173

 
108


14. Contractual Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next eight years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended June 30
2017
$
3,310

2018
3,128

2019
2,052

2020
1,366

Thereafter
644

 
$
10,500


Rent expense for the six months ended June 30, 2016 and 2015, was approximately $859,000 and $593,000, respectively, and was approximately $436,000 and $310,000 for the three months ended June 30, 2016 and 2015, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit
As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $118,000. These obligations are reduced at various times over the life of the lease.
FDA Untitled Letter and Draft Guidance
On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has

18


been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has indicated that it will hold a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The hearing was originally scheduled for April 13, 2016, but was rescheduled to September 2016 in order to allow stakeholders additional time to provide comments due to the considerable interest in the hearing. The Company has requested, and has been granted, an opportunity to speak at the rescheduled hearing. The FDA has also scheduled a related scientific workshop to be held prior to the hearing to identify and discuss the scientific considerations and challenges to help inform the development of HCT/Ps.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues for the fiscal year ended December 31, 2015.

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Norther District of Georgia against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached an amicable settlement of the False Advertising Claims for an undisclosed sum. The patent infringement claims are still pending as described below.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below.

In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the ’437 and ’687 Patents, seeking a partial stay of the litigation as to the ’437, ’687, and ’494 Patents (i.e., the ’437 Patent family). MiMedx opposed the Motion to Stay with respect to the ’494 Patent and once again successfully defeated Defendants’ motion to stay.


19




On December 22, 2015, a Markman Hearing was held before a Special Master. Over thirty disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for one term, the Special Master’s Report essentially adopted MiMedx’s proposed constructions. On March 9, 2016, the Court adopted the Special Master’s Report. Since then the Court has entered a scheduling order in this action. Fact discovery has closed and the parties are currently engaging in expert discovery, which is expected to close in early September 2016. We expect the case to go to trial in late 2016.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, Defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. The Markman hearing in this case was held on October 2, 2015. Except for one term, the Court adopted MiMedx’s proposed construction of the disputed terms. Fact discovery has closed and the parties are currently engaging in expert discovery, which is expected to close in August 2016. We expect the case to go to trial in the fall of 2016.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On November 24, 2015, the court ruled on NuTech’s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement, as well as violations of the Lanham Act which are still pending.

On January 8, 2016, the parties submitted their Initial Disclosures, and MiMedx submitted its preliminary infringement contentions. On March 14, 2016, Defendants submitted their preliminary invalidity contentions. On April 15, 2016, the parties exchanged proposed terms for construction and over the next several months the parties will engage in claim construction briefing and related proceedings. Discovery is ongoing.

The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "494" patent). Vivex answered MiMedx’s Complaint and filed Counterclaims of noninfringement and invalidity.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "687" patent) and the 494 patent; while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

20



On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all seven challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The parties decided to forego oral arguments. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment not configuration, were invalid for obviousness. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. A decision is expected no later than August of 2016.

15. Subsequent Events
None


21


Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
 Three and Six Months Ended June 30, 2016 and 2015 (in thousands)
 
 
 
 
 
 
 
 
Balance at
Beginning of Period
Additions charged to Expense or Revenue
Deductions
and write-offs
Balance at
End of Period
 
 
 
 
 
 
For the three months ended June 30, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
3,872

$
233

$
(19
)
$
4,086

 Allowance for product returns
 
1,708

2,106

(1,623
)
2,191

 Allowance for obsolescence
 
604

1,335

(159
)
1,780

 
 
 
 
 
 
For the three months ended June 30, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
2,010

$
500

$
(6
)
$
2,504

 Allowance for product returns
 
944

734

(648
)
1,030

 Allowance for obsolescence
 
552

90

(89
)
553

 
 
 
 
 
 
For the six months ended June 30, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
3,270

$
835

$
(19
)
$
4,086

 Allowance for product returns
 
1,262

3,467

(2,538
)
2,191

 Allowance for obsolescence
 
397

1,570

(187
)
1,780


 
 
 
 
 
For the six months ended June 30, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
1,750

$
760

$
(6
)
$
2,504

 Allowance for product returns
 
841

1,443

(1,254
)
1,030

 Allowance for obsolescence
 
527

221

(195
)
553



22


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial product families include: dHACM family with AmnioFix® and  EpiFix® brands, Amniotic Fluid family with OrthoFlo brand, Umbilical family with EpiCord™ and AmnioCord™ brands, Placental Collagen family with CollaFix™ brands, Bone family with Physio® brand, and Skin family with AlloBurn™ brand. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane derived from donated placentas. Elected in advance of delivery through our donor program, a mother delivering a healthy baby via scheduled full-term Caesarean section birth may donate the placenta in lieu of having it discarded as medical waste.  We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 600,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.  Recently introduced OrthoFlo is an amniotic fluid derived allograft for homologous use.  Amniotic fluid is donated by a consenting mother delivering a full-term healthy baby by scheduled Caesarean section. Through the recent acquisition of Stability Biologics,  our newest proprietary platforms include Physio, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a  demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn, a skin product for burns.  CollaFix, our next brand in our Placental Collagen family we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.  CollaFix is the only known biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.  The Company's wholly-owned subsidiary, Stability Biologics, LLC, is accredited by the American Association of Tissue Banks (AATB) and registered with the FDA. The Company distinguishes its revenue in two primary regenerative medicine specialties of "Wound Care" and "SSO."  The Company defines SSO as surgical, sports medicine and orthopedics with spinal procedures included in orthopedics and abdominal, and lower pelvic procedures included in surgical.

Recent Events

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially, the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to the Company 16 months earlier. The Company submitted comments to the Minimal Manipulation draft guidance asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/ P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has indicated that it will hold a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The hearing was originally scheduled for April 13, 2016, but was rescheduled to allow stakeholders additional time to provide comments due to the considerable interest in the hearing. The Company has been granted an opportunity to speak at the rescheduled hearing. The FDA has also scheduled a related scientific workshop to be held prior to the hearing to identify and discuss the scientific considerations and challenges to help inform the development of HCT/Ps.




23


Results of Operations Comparison for the Three Months Ended June 30, 2016, to the Three Months Ended June 30, 2015
Revenue
Total revenue increased approximately $11.7 million, or 26%, to $57.3 million for the three months ended June 30, 2016, as compared to $45.7 million for the three months ended June 30, 2015. Wound care revenue for the three months ended June 30, 2016 grew by $6.4 million, or approximately 18%, to $42.0 million, compared to $35.6 million for the three months ended June 30, 2015. SSO revenue for the three months ended June 30, 2016 grew by $5.1 million, or approximately 54.3%, to $14.5 million compared to $9.4 million for the three months ended June 30, 2015.
Tissue Processing Costs and Cost of Products Sold
Cost of products sold as a percentage of revenue increased to 12.9% from 11.1% compared to the prior year as a result of additional costs incurred in connection with the integration of Stability, an increase in the cost of sales related to the purchase accounting inventory step up of approximately $597,000 as well as changes in product mix. Cost of goods sold excluding the inventory step up was 11.9%.
Research and Development Expenses 
The Company's research and development expenses (“R&D expenses”) increased approximately $1.1 million, or 54%, to $3.2 million during the three months ended June 30, 2016, compared to approximately $2.1 million in the prior year. The increase is primarily related to increased investments in scientific studies, clinical trials and personnel costs.

R&D expenses consist primarily of internal personnel costs, expenses of clinical trials, fees paid to external consultants, and the cost of supplies and instruments used in the Company's laboratories.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses for the three months ended June 30, 2016, increased approximately $10.1 million to $42.8 million compared to $32.7 million for the three months ended June 30, 2015. Selling expense increases were driven by costs associated with expanding the Company's direct sales organization, increased commissions due to higher sales volume and an increase in share-based compensation, and the addition of staff and normal operating costs of Stability Inc. Additional spending increases included one time costs of approximately $138,000 related to the acquisition of Stability Inc., support costs related to medical reimbursement, accounting, information technology infrastructure to help manage the growth of the business, and legal costs due to patent litigation. Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotion and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation.
Income Taxes
The effective tax rate increased approximately 39% when compared to the same period of 2015, primarily due to the valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015.
  
Results of Operations Comparison for the Six Months Ended June 30, 2016, to the Six Months Ended June 30, 2015
Revenue
Total revenue increased approximately $24.3 million, or 28%, to $110.7 million for the six months ended June 30, 2016, as compared to $86.4 million for the six months ended June 30, 2015. Wound care revenue for the six months ended June 30, 2016 grew by $16.0 million, or approximately 24.5%, to $81.4 million, compared to $65.4 million for the six months ended June 30, 2015. SSO revenue for the six months ended June 30, 2016 grew by $8.2 million, or approximately 42.3%, to $27.7 million compared to $19.5 million for the six months ended June 30, 2015.
Tissue Processing Costs and Cost of Products Sold
Cost of products sold as a percentage of revenue increased to 13.9% from 11.8% compared to the prior year as a result of additional costs incurred in connection with the integration of Stability Inc., an increase in the cost of sales related to the purchase accounting inventory step up of approximately $1,331,000 as well as changes in product mix. Cost of goods sold excluding the inventory step up was 12.7%.


24


Research and Development Expenses 
The Company's R&D expenses increased approximately $1.8 million, or 46%, to $5.7 million during the six months ended June 30, 2016, compared to approximately $3.9 million in the prior year. The increase is primarily related to increased investments in scientific studies, clinical trials and personnel costs.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses for the six months ended June 30, 2016, increased approximately $21.4 million to $83.4 million compared to $62.0 million for the six months ended June 30, 2015. Selling expense increases were driven by costs associated with expanding the Company's direct sales organization, increased commissions due to higher sales volume and an increase in share-based compensation, and the addition of staff and normal operating costs of Stability Inc. Additional spending increases included one time costs of approximately $851,000 related to the acquisition of Stability Inc., support costs related to medical reimbursement, accounting, information technology infrastructure to help manage the growth of the business, and legal costs due to patent litigation Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotion and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation.
Income Taxes
The effective tax rate increased approximately 31% when compared to the same period of 2015, primarily due to the valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015.

Liquidity and Capital Resources
As of June 30, 2016, the Company had approximately $23.8 million of cash and cash equivalents. The Company reported total current assets of approximately $101.8 million and total current liabilities of approximately $38.5 million at June 30, 2016, which represents a current ratio of 2.6 as of June 30, 2016.

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement established a senior secured revolving credit facility in favor of the Company, with an aggregate lender commitment of up to $50 million. As of the date hereof, there are no outstanding revolving loans under the Credit Agreement. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The Credit Agreement contains customary covenants and events of default for senior secured credit agreements of this type. The covenants include (a) a requirement for the Company to maintain a maximum consolidated leverage ratio of 2.50:1.00; (b) a requirement for the Company to maintain a minimum consolidated fixed charge coverage ratio of 2.00:1.00; and (c) a requirement for the Company to maintain minimum liquidity of $10 million. The Company is currently in compliance with all of its covenants.

For the six months ended June 30, 2016, in connection with the acquisition of Stability Inc., the Company paid approximately $6 million in cash for the initial purchase price, paid off debt of approximately $1.8 million and provided initial working capital of approximately $4 million.
For the six months ended June 30, 2016, the Company purchased 415,252 shares of its common stock for a purchase price of approximately $3,518,000, before brokerage commissions of approximately $12,000 bringing the total amount spent under the program to approximately $49,244,000 since inception. As of June 30, 2016, the Company had approximately $10,756,000 of availability remaining under the repurchase program. The timing and amount of future repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
In addition, during the six months ended June 30, 2016, the Company purchased 81,594 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.
We believe that our anticipated cash from operating activities, existing cash and cash equivalents, and availability under the Credit Agreement will enable us to meet our operational liquidity needs and fund our planned investing activities for the next year.

Contingencies

25


See Note 14 to our Condensed Consolidated Financial Statements in Part I, Item 1 herein.
Contractual Obligations
Contractual obligations associated with ongoing business activities are expected to result in cash payments in future periods.  The table below summarizes the amounts and estimated timing of these future cash payments as of June 30, 2016 (in thousands):
 
 
 
Less than
 
 
 
 
 
 
Contractual Obligations
TOTAL
 
1 year
 
1-3 years
 
3-5 years
 
Thereafter
Capital lease obligations
$
72

 
$
57

 
$
15

 
$
—

 
$
—

Operating lease obligations
8,033

 
2,097

 
3,972

 
1,518

 
446

Charitable contribution obligations
475

 
475

 
—

 
—

 
 
Software license
331

 
95

 
189

 
47

 
 
Meeting space commitments
1,661

 
643

 
1,018

 
—

 
 
 
$
10,572

 
$
3,367

 
$
5,194

 
$
1,565

 
$
446

Discussion of cash flows
Net cash from operations during the six months ended June 30, 2016 decreased approximately $0.8 million to approximately $6.3 million compared to $7.1 million from operating activities for the six months ended June 30, 2015, primarily attributable to a decrease in net income compared to the prior year, as well as post acquisition working capital costs for Stability Inc. For the three months ended June 30, 2016, operating cash increased approximately $4.4 million as compared to the three months ended June 30, 2015, primarily due to increased cash collections resulting in smaller increases in accounts receivable offset by a decrease in net income.
Net cash used in investing activities during the six months ended June 30, 2016 was approximately $8.7 million compared to approximately $1.2 million for 2015. Cash used for the acquisition of Stability Inc. totaled $7.6 million, $3.8 million of which was used for the purchase of equipment to expand production capacity, partially offset by maturing certificates of deposit of $3 million. For the three months ended June 30, 2016 cash attributed to investing activities increased approximately $700,000 as compared to the three months ended June 30, 2015, primarily due to maturing certificates of deposit offset by higher purchases of equipment.
Net cash used in financing activities during the six months ended June 30, 2016 decreased approximately $11.7 million to $2.3 million compared to $14.0 million of cash used during the six months ended June 30, 2015. Cash flows used in financing activities during the six months ended June 30, 2016 included approximately $4.2 million for stock repurchases compared to $16.6 million in the prior year. Additionally, the Company received $2.0 million from the exercise of stock options compared to approximately $2.7 million in the prior year. For the three months ended June 30, 2016, cash attributed to financing activities increased by $3.7 million as compared to the three months ended June 30, 2015, primarily due to a greater amount of stock repurchases in 2015.
Non-GAAP Financial Measures
In addition to our GAAP results, we provide certain Non-GAAP metrics including Adjusted EBITDA, Adjusted Gross Margin, Adjusted Net Income and Adjusted Diluted Net Income per share. Adjusted EBITDA consists of GAAP Net Income excluding: (i) depreciation and amortization, (ii) other income (expense), (iii) interest income and expense, (iv) income taxes, (v) one time acquisition related costs, (vi) the effect of purchase accounting due to acquisitions and (vii) share-based compensation expense. The Company believes that the presentation of these measures provides important supplemental information to management and investors regarding the operational use of cash. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against other medical technology companies. Adjusted Gross Margin consists of GAAP gross margin excluding amortization of inventory fair value step-up. Adjusted net income and diluted net income per share consists of GAAP net income excluding: (i) one time acquisition related costs, (ii) amortization of inventory fair value step-up, (iii) amortization of intangible assets and (iv) share-based compensation. Due to the impact of the acquisition of Stability Inc. in January 2016 and the release of the valuation allowance on the deferred tax asset on reported tax expense in 2015 on results, the Company has decided to provide adjusted non-GAAP measures to provide comparability of normal ongoing operating results. Beginning last quarter, the Company has reported Adjusted Gross Margin, Adjusted Net Income and Adjusted EPS to normalize results for comparison purposes in addition to reporting GAAP results as

26


summarized below. Reconciliations of GAAP net income to Adjusted EBITDA, GAAP Gross Margin to Adjusted Gross Margin and GAAP Net Income to Adjusted Net Income for the three months and six months ended June 30, 2016 and 2015 appear in the tables below.
The Company's Adjusted EBITDA for the three months ended June 30, 2016, was approximately $10.1 million which is a reduction of $(0.5) million as compared to the three months ended June 30, 2015. The reduction was attributable to increased investments in support of growth of the business compared to the prior year. The Company's Adjusted EBITDA for the six months ended June 30, 2016, was approximately $19.1 million which is a reduction of $(0.2) million as compared to the six months ended June 30, 2015. The reduction was attributable to increased investments in support of growth of the business compared to the prior year.
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Net Income (Per GAAP)
$
1,975

 
$
5,430

 
$
3,172

 
$
9,517

 
 
 
 
 
 
 
 
Add back:
 
 
 
 
 

 
 
Income taxes
1,475

 
223

 
1,689

 
369

One time costs incurred in connection with acquisition
138

 
—

 
851

 
—

One time inventory costs incurred in connection with acquisition
597

 
—

 
1,331

 
—

Other interest (income) expense, net
111

 
(1
)
 
167

 
13

Depreciation expense
821

 
422

 
1,555

 
776

Amortization of intangible assets
447

 
233

 
1,257

 
465

Share-based compensation
4,509

 
4,254

 
9,124

 
8,186

Adjusted EBITDA
$
10,073

 
$
10,561

 
$
19,146

 
$
19,326


Reconciliation of "Adjusted Gross Margin" defined as Gross Margin before Amortization of inventory fair value step-up (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Gross Margin (Per GAAP)
$
49,948

 
$
40,590

 
$
95,369

 
$
76,209

 
 
 
 
 
 
 
 
Non-GAAP Adjustments:
 
 
 
 
 
 
 
One time inventory costs incurred in connection with acquisition
597

 
—

 
1,331

 
—

Gross Margin before Amortization of inventory fair value step-up
$
50,545

 
$
40,590

 
$
96,700

 
$
76,209

Adjusted Gross Margin
88.2
%
 
88.9
%
 
87.3
%
 
88.2
%
Reconciliation of Net Income "Adjusted Earnings per Share" defined as Net Income less Amortization, One Time Costs and Share-Based Compensation (in thousands, except share and per share data):

27


 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Net Income (Per GAAP)
$
1,975

 
$
5,430

 
$
3,172

 
$
9,517

 
 
 
 
 
 
 
 
Non-GAAP Adjustments:
 
 
 

 
 

 
 

Tax rate normalization*
(12
)
 
(2,153
)
 
(362
)
 
(3,787
)
One time costs incurred in connection with acquisition
138

 
—

 
851

 
—

One time inventory costs incurred in connection with acquisition
597

 
—

 
1,331

 
—

Amortization of intangible assets
447

 
233

 
1,257

 
465

Share - based compensation
4,509

 
4,254

 
9,124

 
8,186

Estimated income tax impact from adjustments*
(2,525
)
 
(1,886
)
 
(5,302
)
 
(3,637
)
Adjusted Net Income
$
5,129

 
$
5,878

 
$
10,071

 
$
10,744

Adjusted diluted net income per share
$
0.05

 
$
0.05

 
$
0.09

 
$
0.09

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,148,415

 
114,186,329

 
112,095,051

 
113,892,087

*Assumes a normalized tax rate of 42% for 2015 and 42% for 2016.
Critical Accounting Policies
In preparing financial statements, the Company follows accounting principles generally accepted in the United States, which require the Company to make certain estimates and apply judgments that affect its financial position and results of operations. Management continually reviews the Company's accounting policies and financial information disclosures. A summary of significant accounting policies that require the use of estimates and judgments in preparing the financial statements was provided in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.  During the quarter covered by this report, there were no material changes to the accounting policies and assumptions previously disclosed.
Recent Accounting Pronouncements
For the effect of recent accounting pronouncements, see Note 2 to the Condensed Consolidated Financial Statements contained herein.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk

Based on our lack of market risk sensitive instruments outstanding at June 30, 2016, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.

28


Item 4. Controls and Procedures
Disclosure Controls and Procedures
As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered by this report. This evaluation was carried out under the supervision and with the participation of Company management, including its Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's controls and procedures were effective as of the end of the period covered by this report.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company's reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in the Company's reports filed under the Exchange Act is accumulated and communicated to management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding disclosures.
Changes in Internal Control over Financial Reporting
There was no change in the Company's internal control over financial reporting that occurred during the quarter ended June 30, 2016, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
Limitations on the Effectiveness of Controls
The Company has confidence in its internal controls and procedures. Nevertheless, management, including the Company's Chief Executive Officer and Chief Financial Officer, does not expect that the Company's disclosure procedures and controls or its internal controls will prevent all errors or intentional fraud. An internal control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of such internal controls are met. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all internal control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings

We are a party to various legal claims and actions incidental to our business. These items are more fully discussed in Note 14 to our Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.

29


Item 6. Exhibits
Exhibit
Number
Reference
Description
 
 
 
2.1##
 
Agreement and Plan of Merger dated January 10, 2016, by and among MiMedx Group, Inc., Titan Acquisition Sub I, Inc., Titan Acquisition Sub II, LLC, Stability Inc., certain stockholders of Stability Inc. and Brian Martin as representative of the Stability stockholders (incorporated by reference to Exhibit 2.1 filed with Registrant's Form 8-K filed on January 13, 2016)
3.1
 
Articles of Incorporation as filed with the Secretary of State of Florida on March 31, 2008 (incorporated by reference to Exhibit 3.1 filed with the Registrant's Form 10-Q on August 8, 2013)
3.2
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on May 14, 2010 (incorporated by reference to Exhibit 3.2 filed with the Registrant's Form 10-Q on August 8, 2013)
3.3
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on August 8, 2012 (incorporated by reference to Exhibit 3.3 filed with the Registrant's Form 10-Q on August 8, 2013)
3.4
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on November 8, 2012 (incorporated by reference to Exhibit 3.4 filed with the Registrant's Form 10-Q on August 8, 2013)
3.5
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on May 15, 2015  (incorporated by reference to Exhibit 3.5 filed with the Registrant's Form 10-Q on August 7, 2015)
3.6
 
Bylaws of MiMedx Group, Inc. (incorporated by reference to Exhibit 3.2 filed with Registrant's Form 8-K filed on April 2, 2008)
3.7
 
Amendment to the Bylaws of MiMedx Group, Inc. adopted by the Board of Directors on May 11, 2010 (incorporated by reference to Exhibit 3.2 to the Registrant's Form 8-K filed on May 14, 2010)
10.1*
 
MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (incorporated herein by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A (File No. 001-35887), filed April 12, 2016)
10.2#*
 
Form of Incentive Stock Option Agreement

10.3#*

 
Form of Restricted Stock Agreement
10.4#*
 
Form of Nonqualified Stock Option Agreement
10.5*
 
Change in Control Severance Compensation and Restrictive Covenant Agreement dated as of May 20, 2016 by and between MiMedx Group, Inc. and Alexandra O. Haden (incorporated by reference to Exhibit 10.1 filed with Registrant's Form 8-K filed on May 25, 2016)
31.1 #
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 #
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 #
 
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2 #
 
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 

30


#
Filed herewith
##
Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K, but a copy will be furnished supplementally to the Securities and Exchange Commission upon request)





*
Indicates a management contract or compensatory plan or arrangement



31


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
August 2, 2016
 
 
 
By:
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer
 
 
(principal financial and accounting officer)

32
 EX-10.2 2 a10-q63016exhibit101.htm EXHIBIT 10.2 Exhibit


MIMEDX GROUP, INC.
2016 EQUITY AND CASH INCENTIVE PLAN

Incentive Stock Option Agreement


No. of shares subject to
Incentive Stock Option: __________
THIS INCENTIVE STOCK OPTION AGREEMENT (this “Agreement”) dated as of the ____ day of __________, 201_, between MiMedx Group, Inc. (the “Company”), and ____________________ (the “Participant”), is made pursuant and subject to the provisions of the Company’s 2016 Equity and Cash Incentive Plan (the “Plan”), a copy of which is attached hereto. All terms used herein that are defined in the Plan have the same meaning given them in the Plan.
1.Grant of Option. Pursuant to the Plan, the Company, on ____________, 201_ (the “Date of Grant”), granted to the Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions set forth herein, the right and option to purchase from the Company all or any part of an aggregate of ________ shares of the Common Stock of the Company, at the price of $________ per share (which is not less than the Fair Market Value of a share of Common Stock on the Date of Grant (110% of the Fair Market Value if the Participant is a Ten Percent Shareholder)) (this "Option"). This Option is intended to be treated as an “incentive stock option” (as defined in Section 422 of the Code), but only to the extent the aggregate Fair Market Value (determined as of the Date of Grant) of the shares of Common Stock for which this Option (and all other options of the Participant that are intended to be incentive stock options whether granted under the Plan or any other plan of the Company or any of its Affiliates) becomes exercisable for the first time in any calendar year does not exceed One Hundred Thousand Dollars ($100,000). If that limitation is exceeded, this Option may be exercised for the excess number of shares as a nonqualified stock option. Notwithstanding the foregoing, however, the Company shall not be liable to the Participant if this Option or any portion thereof fails to qualify as an incentive stock option. This Option is exercisable as hereinafter provided.

2.Terms and Conditions. This Option is subject to the following terms and conditions:

(a)Expiration Date. This Option shall expire at 11:59 p.m. on __________, 202_ (the “Expiration Date”) or such earlier time as set forth in this Agreement. In no event shall the Expiration Date be later than 10 years after the Date of Grant (5 years if the Participant is a Ten Percent Shareholder).

(b)Vesting of Option. Except as otherwise provided below, this Option shall become vested and exercisable with respect to one-third (1/3) of the shares of Common Stock subject to the Option (rounded to the nearest whole share) on each of the first and second anniversaries of the Date of Grant, and with respect to the remaining shares of Common Stock subject to the Option on the third anniversary of the Date of Grant, provided in each case the Participant has been continuously employed by the Company or an Affiliate from the Date of Grant until such time(s). Once this Option has become vested and exercisable, it shall continue to be vested and exercisable until the earlier of the termination of the Participant’s rights hereunder or the Expiration Date. A partial exercise of this Option shall not affect the Participant’s right to exercise this Option with respect to the remaining shares of Common Stock, subject to the terms of the Plan and this Agreement.

(c)Change in Control. Notwithstanding the foregoing, the Option shall become vested and exercisable on a Change in Control with respect to all of the shares of Common Stock subject to the




Option, to the extent not already vested and exercisable, provided the Participant has been continuously employed by, or providing services to, the Company or an Affiliate from the Date of Grant until the time of the Change in Control.

(d)Death or Disability. Additionally, the Option shall become vested and exercisable with respect to all of the shares of Common Stock subject to the Option on the termination of the Participant's employment by, or provision of services to, the Company and its Affiliates, to the extent not already vested and exercisable, if the Participant's employment by, or provision of services to, the Company and its Affiliates terminates on account of the Participant's death or Disability.

(e)Method of Exercise and Payment for Shares. To the extent then vested and exercisable, the Participant may exercise the Option by delivering written notice of exercise, along with the exercise price for the portion of the Option being exercised, to the attention of the Company’s Secretary at the Company’s address specified in Section 8 below. Notwithstanding the foregoing, no single exercise of the Option may be for less than 100 shares of Common Stock unless, at the time of exercise, the maximum number of shares of Common Stock available for purchase under the Option is less than 100 shares, in which event the Option may be exercised, if at all, only for all of the shares of Common Stock then available for purchase. The exercise date shall be the date of the notice. The Participant shall pay the exercise price in cash or cash equivalent acceptable to the Committee. However, the Committee in its discretion may, but is not required to, allow the Participant to pay the exercise price (i) by surrendering shares of Common Stock the Participant already owns, (ii) by a cashless exercise through a broker, (iii) by means of a “net settlement” procedure, (iv) by such other medium of payment as the Committee shall authorize or (v) by any combination of the allowable methods of payment set forth herein. If payment is in the form of shares of Common Stock, then the certificate or certificates representing those shares must be duly executed in blank by the Participant or accompanied by a stock power duly executed in blank suitable for purposes of transferring those shares to the Company. Fractional shares of Common Stock will not be accepted in payment of the exercise price of the Option. The Company will not issue the shares of Common Stock until full payment of the exercise price for them has been made. As soon as administratively practicable upon the Company's receipt of the exercise price, subject to the other terms of the Option, the Company shall direct the issuance of the applicable shares of Common Stock so purchased. In the case of the Participant’s death, the Option to the extent vested and exercisable, may be exercised by the executor or administrator of the Participant’s estate or by any person or persons who have acquired the Option directly from the Participant by bequest or inheritance.

(f)Non-Transferability of Option. The Participant shall not assign or transfer the Option, other than by will or the laws of descent and distribution. During the Participant’s lifetime, only the Participant (or, in the event of legal incapacity or incompetency, the Participant’s guardian or legal representative) may exercise the Option. Notwithstanding the foregoing, this Option may be transferred by will or the laws of descent and distribution. No right or interest of the Participant or any transferee in this Option shall be liable for, or subject to, any lien, obligation or liability of the Participant or any transferee.

(g)Stock Holding Requirements. Notwithstanding any other provision of this Agreement, shares of Common Stock acquired pursuant to this Option may not be sold, transferred or otherwise disposed of until the level of ownership provided in the Company’s Stock Ownership Guidelines is met, to the extent applicable to the Participant. All shares of Common Stock acquired under the Plan (“net” shares acquired in case of any net exercise or withholding of shares) shall be subject to the terms and conditions of the Company’s Stock Ownership Guidelines, as they may be amended from time to time.





3.Termination of Option.

(a)Exercise in the Event of Death, Disability or Retirement. This Option shall be exercisable for all or part of the number of shares of Common Stock that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant's employment by, or provision of services to, the Company and its Affiliates, reduced by the number of shares for which the Participant previously exercised the Option, to the extent the Participant’s rights have not otherwise been terminated under this Agreement, if the Participant's employment by, or provision of services to, the Company and its Affiliates terminates on account of the Participant's death, Disability or Retirement. In that event, this Option may be exercised by the Participant, the Participant’s estate, or the person or persons to whom the Participant’s rights under this Option shall pass by will or the laws of descent and distribution (to the extent applicable), for the remainder of the period preceding the Expiration Date or until the date that is twelve (12) months after the Participant’s Termination Date due to death, Disability or Retirement, whichever period is shorter. Notwithstanding the foregoing, to the extent the Participant exercises any portion of this Option more than three (3) months after the date the Participant ceases to be an employee of the Company and its Affiliates, such portion of the Option shall be treated as a nonqualified stock option.

(b)Exercise after a Change of Control. This Option shall be exercisable for all or part of the number of shares of Common Stock that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant's employment by, or provision of services to, the Company and its Affiliates on or after a Change in Control, reduced by the number of shares for which the Participant previously exercised the Option, to the extent the Participant’s rights have not otherwise been terminated under this Agreement, if the Participant's employment by, or provision of services to, the Company and its Affiliates terminates on or after a Change in Control (other than as described in Section 3(a) above). In that event, the Participant may exercise this Option for the remainder of the period preceding the Expiration Date or until the date that is six (6) months after the Participant's Termination Date, whichever period is shorter. Notwithstanding the foregoing, to the extent the Participant exercises any portion of this Option more than three (3) months after the date he ceases to be an employee of the Company and its Affiliates, such portion of the Option shall be treated as a nonqualified stock option.

(c)Exercise after other Termination of Employment or Service. This Option shall be exercisable for all or part of the number of shares of Common Stock that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant's employment by, or provision of services to, the Company and its Affiliates, reduced by the number of shares for which the Participant previously exercised the Option, to the extent the Participant's rights have not otherwise terminated under this Agreement, if the Participant's employment by, or provision of services to, the Company and its Affiliates terminates other than under any of the circumstances set forth in Sections 3(a) or (b) of this Agreement, for the remainder of the period preceding the Expiration Date or until the date that is three (3) months after the Participant's Termination Date, whichever period is shorter.

(d)Termination. The Option or portion thereof not either terminated or exercised at such time will terminate automatically and without further notice at the time the Option can no longer be exercised as set forth above.

(e)For Cause. Notwithstanding any other provision of this Agreement, the Option will terminate automatically upon the termination of the Participant's employment by, or provision of services




to, the Company and its Affiliates for Cause, immediately upon notice of such termination (including any portion of the Option that may have become vested and exercisable previously).

4.Agreement to Terms of the Plan and Agreement. The Participant has received a copy of the Plan, has read and understands the terms of the Plan and this Agreement, and agrees to be bound by their terms and conditions. All decisions and interpretations made by the Company or the Committee with regard to any question arising under this Option will be binding and conclusive on the Company and the Participant and any other person entitled to exercise the Options as provided for in this Agreement.

5.Tax Consequences. The Participant acknowledges (i) that there may be adverse tax consequences upon acquisition or disposition of the shares of Common Stock received upon exercise of this Option and (ii) that Participant should consult a tax adviser prior to such acquisition or disposition. The Participant is solely responsible for determining the tax consequences of the Option and for satisfying the Participant’s tax obligations with respect to the Option (including, but not limited to, any income or excise tax as resulting from the application of Code Sections 409A or 4999 or related interest and penalties), and the Company and its Affiliates shall not be liable if this Option is subject to Code Sections 409A, 280G or 4999. The Company’s obligation to deliver shares of Common Stock upon exercise of the Option is subject to the Participant’s satisfaction of any applicable federal, state and local income and employment tax and withholding requirements in a manner and form satisfactory to the Company. The Committee, to the extent applicable law permits, may allow the Participant to pay any such amounts (but only for the minimum required withholding or such other amounts as will not otherwise have negative accounting consequences) (i) by surrendering (actual or by attestation) shares of Common Stock that the Participant already owns; (ii) by a cashless exercise though a broker, (iii) by means of a “net exercise” procedure or (iv) by such other medium of payment as the Committee in its discretion shall authorize.

6.Fractional Shares. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle the Participant to a fractional share such fractional share shall be disregarded.

7.Change in Capital Structure. The terms of this Option shall be adjusted in accordance with the terms and conditions of the Plan as the Committee determines is equitably required in the event the Company effects one or more stock dividends, stock splits, subdivisions or consolidations of shares or other similar changes in capitalization.

8.Notice. Any notice or other communication given pursuant to this Agreement, or in any way with respect to this Option, shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the following addresses:





If to the Company:    MiMedx Group, Inc.
1775 West Oak Commons Ct. NE
Marietta, Georgia 30062
Attn: ___________________

If to the Participant:    ______________________________
______________________________
______________________________

9.     Shareholder Rights. The Participant shall not have any rights as a shareholder with respect to shares of Common Stock subject to this Option until the issuance of the shares of the Common Stock upon exercise of the Option.

10.     No Right to Continued Employment. Neither the Plan, the granting of this Option nor any other action taken pursuant to the Plan or this Option constitutes or is evidence of any agreement or understanding, expressed or implied, that the Company or any Affiliate shall retain the Participant as an employee for any period of time or at any particular rate of compensation.

11.     Binding Effect. Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of the Participant and the successors of the Company.

12.     Conflicts. In the event of any conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall govern. All references herein to the Plan shall mean the Plan as in effect on the date hereof.

13.     Counterparts. This Agreement may be executed in a number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one in the same instrument.

14.     Miscellaneous. The parties agree to execute such further instruments and take such further actions as may be necessary to carry out the intent of the Plan and this Agreement. This Agreement and the Plan shall constitute the entire agreement of the parties with respect to the subject matter hereof.

15.     Section 409A. Notwithstanding any of the provisions of this Agreement, it is intended that the Option be exempt from Section 409A of the Code. Notwithstanding the preceding, neither the Company nor any Affiliate shall be liable to the Participant or any other person if the Internal Revenue Service or any court or other authority have any jurisdiction over such matter determines for any reason that the Option is subject to taxes, penalties or interest as a result of failing to be exempt from, or comply with, Section 409A of the Code.

16.     Notice Upon Sale. The Participant shall notify the Company of any sale or other disposition of shares of Common Stock acquired pursuant to this Option if such sale or disposition occurs (a) within two (2) years after the Date of Grant or (b) within one (1) year after the issuance of shares of Common Stock to the Participant. Such notice shall be in writing and directed to the Company’s Secretary at the Company’s address specified in Section 8 above.

17.     Compensation Recoupment Policy. Notwithstanding any other provision of this Agreement, the Participant shall reimburse or return to the Company the gross number of shares of Common Stock that the Participant received (or would have received absent a “net exercise” procedure)




under this Agreement or, if greater, the amount of gross proceeds from any earlier sale of any such shares of Common Stock, plus any other amounts received with respect to this Award, to the extent any reimbursement, recoupment or return is required under applicable law or the Company’s Compensation Recoupment Policy or any similar policy that the Company may adopt.

18.     Governing Law. This Agreement shall be governed by the governing laws applicable to the Plan.

[Signatures continued on next page]



































IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and the Participant has affixed the Participant’s signature hereto.

COMPANY:
MIMEDX GROUP, Inc.
By:    ___________________________________    
Name:    ___________________________________
Title:    ___________________________________
PARTICIPANT:
_________________________________________    
[Participant’s Name]




 EX-10.3 3 a10-q63016exhibit103.htm EXHIBIT 10.3 Exhibit


MIMEDX GROUP, INC.
2016 EQUITY AND CASH INCENTIVE PLAN
Restricted Stock Agreement
No. of shares
of Restricted Stock: _________
THIS RESTRICTED STOCK AGREEMENT (this "Agreement") dated as of the _____ day of                 , 201___, between MiMedx Group, Inc. (the "Company") and _________________ (the "Participant"), is made pursuant and subject to the provisions of the Company's 2016 Equity and Cash Incentive Plan (the "Plan"), a copy of which is attached hereto. All terms used herein that are defined in the Plan have the same meaning given them in the Plan.
1.Grant of Restricted Stock. Pursuant to the Plan, the Company, on ___________ ____, 201__ (the "Date of Grant"), granted to the Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions set forth herein, this Restricted Stock Award for ______ shares of Common Stock (the "Shares"). The Shares are nontransferable and forfeitable until the time they vest and become nonforfeitable as described herein. The Shares will vest and become nonforfeitable as set forth in Section 2 below.

2.Vesting of the Shares. Subject to earlier expiration or termination as provided herein, the Shares will become vested and nonforfeitable as follows:

(a)Time-Based Vesting. The Shares will become vested and nonforfeitable with respect to one-third (1/3) of the Shares (rounded to the nearest whole Share) on each of the first and second anniversaries of the Date of Grant, and with respect to the remaining Shares on the third anniversary of the Date of Grant, provided the Participant has been continuously employed by, or providing services to, the Company or an Affiliate from the Date of Grant until such time(s).

(b)Change of Control. Notwithstanding the foregoing, upon the occurrence of a Change of Control, the Shares shall become vested and nonforfeitable at the time of the Change of Control, provided the Participant has been continuously employed by, or providing services to, the Company or an Affiliate from the Date of Grant until the time of the Change of Control.

(c)Death and Disability. Additionally, if the Participant's employment with the Company and its Affiliates is terminated on account of the Participant's death or Disability, the Shares shall become vested and nonforfeitable on termination of the Participant's employment with the Company and its Affiliates on account of the Participant's death or Disability.

3.Non-Transferability of the Shares.

(a)Transfer Restrictions. Participant shall not assign or transfer any Shares while such Shares remain forfeitable, other than by will or the laws of descent and distribution. No right or interest of Participant or any transferee in the Shares shall be subject to any lien or any obligation or liability of the Participant or any transferee.

(b)Stock Holding Requirements. Notwithstanding any other provision of this Agreement, the shares that vest and become nonforfeitable may not be sold, transferred or otherwise




disposed of until the level of ownership provided in the Company’s Stock Ownership Guidelines is met, to the extent applicable to the Participant. All shares of Common Stock acquired hereunder (“net” shares acquired in case of any net exercise or withholding of shares) shall be subject to the terms and conditions of the Company’s Stock Ownership Guidelines, as they may be amended from time to time.

4.Forfeiture of the Shares. Shares that are not vested and nonforfeitable pursuant to Sections 2(a), (b) or (c) as of the date of termination of Participant’s employment by, or provision of services to, the Company and its Affiliates will be forfeited automatically at the close of business on that date (immediately upon notice of termination for Cause). In no event may the Shares become vested and nonforfeitable, in whole or in part, after forfeiture pursuant to this Section 4.

5.Agreement to Terms of the Plan and this Agreement. The Participant has received a copy of the Plan, has read and understands the terms of the Plan and this Agreement, and agrees to be bound by their terms and conditions. All decisions and interpretations made by the Company or the Committee with regard to any question arising under this Agreement will be binding and conclusive on the Company and Participant and any other person who has any rights under this Agreement.

6.Tax Consequences. The Participant acknowledges (i) that there may be adverse tax consequences upon acquisition or disposition of the shares of Common Stock received upon vesting of the Shares and (ii) that Participant should consult a tax adviser prior to such acquisition or disposition. The Participant is solely responsible for determining the tax consequences of the Restricted Stock Award and for satisfying the Participant’s tax obligations with respect to the Restricted Stock Award (including, but not limited to, any income or excise tax as resulting from the application of Code Sections 409A or 4999 or related interest and penalties), and the Company and its Affiliates shall not be liable if this grant is subject to Code Sections 409A, 280G or 4999. The Company’s obligation to vest shares of Common Stock is subject to the Participant’s satisfaction of any applicable federal, state and local income and employment tax and withholding requirements in a manner and form satisfactory to the Company. The Committee, to the extent applicable law permits, may allow the Participant to pay any such amounts (but only for the minimum required withholding or such other amounts as will not otherwise have negative accounting consequences) (i) by surrendering (actual or by attestation) shares of Common Stock that the Participant already owns; (ii) by a cashless exercise though a broker, (iii) by means of a “net exercise” procedure or (iv) by such other medium of payment as the Committee in its discretion shall authorize.

7.Fractional Shares. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle the Participant to a fractional share such fractional share shall be disregarded.

8.Change in Capital Structure. The Shares shall be adjusted in accordance with the terms and conditions of the Plan as the Committee determines is equitably required in the event the Company effects one or more stock dividends, stock splits, subdivisions or consolidations of shares or other similar changes in capitalization.

9.Notice. Any notice or other communication given pursuant to this Agreement, or in any way with respect to the Shares, shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the following addresses:




If to the Company:    MiMedx Group, Inc.
1775 West Oak Commons Ct. NE
Marietta, Georgia 30062
            

If to the Participant:    The most current participant address
of record on file with the Company

10.Shareholder Rights. While the Shares remain subject to forfeiture in accordance with this Agreement, Participant shall have all rights of a stockholder with respect to such Shares, including the right to receive dividends and vote the Shares; provided, however, that during such period (i) Participant may not sell, transfer, pledge, exchange, hypothecate or otherwise dispose of the Shares other than as described above and (ii) the Company shall retain custody of any certificates evidencing the Shares. In lieu of retaining custody of any certificates evidencing the Shares, the Shares granted under the Agreement, may, in the Company’s discretion, be held in escrow by the Company or reflected in the Company’s books and records, until Participant’s interest in such Shares becomes vested and nonforfeitable. With respect to any Shares forfeited under this Agreement, Participant does hereby irrevocably constitute and appoint the Secretary of the Company or any successor Secretary of the Company (the “Secretary”) as Participant’s attorney to transfer the forfeited Shares on the books of the Company with full power of substitution in the premises. The Secretary shall use such authority to cancel any Shares that are forfeited under this Agreement.

11.No Right to Continued Employment or Service. Neither the Plan, the granting of the Shares nor any other action taken pursuant to the Plan or this Agreement constitutes or is evidence of any agreement or understanding, expressed or implied, that the Company or any Affiliate shall retain the Participant as an employee or other service provider for any period of time or at any particular rate of compensation.

12.Binding Effect. Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of the Participant and the successors of the Company.

13.Conflicts. In the event of any conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall govern. All references herein to the Plan shall mean the Plan as in effect on the date hereof.

14.Counterparts. This Agreement may be executed in a number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one in the same instrument

15.Miscellaneous. The parties agree to execute such further instruments and take such further actions as may be necessary to carry out the intent of the Plan and this Agreement. This Agreement and the Plan shall constitute the entire agreement of the parties with respect to the subject matter hereof.

16.Section 409A. Notwithstanding any of the provisions of this Agreement, it is intended that the Shares be exempt from Section 409A of the Code. Notwithstanding the preceding, neither the Company nor any Affiliate shall be liable to the Participant or any other person if the Internal Revenue Service or any court or other authority have any jurisdiction over such matter determines for any reason




that the Shares are subject to taxes, penalties or interest as a result of failing to be exempt from, or comply with, Section 409A of the Code.

17.Section 83(b). The Participant may make an election under Section 83(b) of the Code to include the Fair Market Value of the Shares in taxable income as of the Date of Grant. Notwithstanding the foregoing, no such election may be made unless the Participant makes arrangements that are satisfactory to the Committee to pay all applicable tax withholdings in cash or cash equivalents or some other acceptable methodology other than by means of a “net exercise” procedure.

18.Compensation Recoupment Policy. Notwithstanding any other provision of this Agreement, the Participant shall reimburse or return to the Company the gross number of shares of Common Stock that the Participant received (or would have received absent a “net exercise” procedure) under this Agreement or, if greater, the amount of gross proceeds from any earlier sale of any such shares of Common Stock, plus any other amounts received with respect to this Award, to the extent any reimbursement, recoupment or return is required under applicable law or the Company’s Compensation Recoupment Policy or any similar policy that the Company may adopt.

19.Governing Law. This Agreement shall be governed by the governing laws applicable to the Plan.


[Signature Page to Follow]





















IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and the Participant has affixed the Participant’s signature hereto.

COMPANY:
MiMedx Group, Inc.


By:    ___________________________________________
Name: Parker H. Petit    
    Its: Chairman of the Board and CEO


ATTEST:
___________________________________________
Thornton A. Kuntz, Jr.
Senior Vice President, Administration    

PARTICIPANT:
_________________________________________________
Participant’s Signature




 EX-10.4 4 a10-q63016exhibt102.htm EXHIBIT 10.4 Exhibit


MIMEDX GROUP, INC.
2016 EQUITY AND CASH INCENTIVE PLAN

Nonqualified Stock Option Agreement

No. of shares subject to
Nonqualified Stock Option: __________
THIS NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated as of the ____ day of __________, 201_, between MiMedx Group, Inc. (the “Company”), and ____________________ (the “Participant”), is made pursuant and subject to the provisions of the Company’s 2016 Equity and Cash Incentive Plan (the “Plan”), a copy of which is attached hereto. All terms used herein that are defined in the Plan have the same meaning given them in the Plan.
1.    Grant of Option. Pursuant to the Plan, the Company, on ____________, 201_ (the “Date of Grant”), granted to the Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions set forth herein, the right and option to purchase from the Company all or any part of an aggregate of ________ shares of the Common Stock of the Company, at the price of $________ per share (which is not less than the Fair Market Value of a share of Common Stock on the Date of Grant) (this "Option"). This Option is intended to be treated as a nonqualified stock option, which is not subject to Section 421 of the Code. This Option is exercisable as hereinafter provided.
2.    Terms and Conditions. This Option is subject to the following terms and conditions:

(a)Expiration Date. This Option shall expire at 11:59 p.m. on __________, 202_ (the “Expiration Date”) or such earlier time as set forth in this Agreement. In no event shall the Expiration Date be later than 10 years after the Date of Grant.

(b)Vesting of Option. Except as otherwise provided below, this Option shall become vested and exercisable with respect to one-third (1/3) of the shares of Common Stock subject to the Option (rounded to the nearest whole share) on each of the first and second anniversaries of the Date of Grant, and with respect to the remaining shares of Common Stock subject to the Option on the third anniversary of the Date of Grant, provided in each case the Participant has been continuously employed by, or providing services to, the Company or an Affiliate from the Date of Grant until such time(s). Once this Option has become vested and exercisable, it shall continue to be vested and exercisable until the earlier of the termination of the Participant’s rights hereunder or the Expiration Date. A partial exercise of this Option shall not affect the Participant’s right to exercise this Option with respect to the remaining shares of Common Stock, subject to the terms of the Plan and this Agreement.

(c)Change in Control. Notwithstanding the foregoing, the Option shall become vested and exercisable on a Change in Control with respect to all of the shares of Common Stock subject to the Option, to the extent not already vested and exercisable, provided the Participant has been continuously employed by, or providing services to, the Company or an Affiliate from the Date of Grant until the time of the Change in Control.

(d)Death or Disability. Additionally, the Option shall become vested and exercisable with respect to all of the shares of Common Stock subject to the Option on the termination of the Participant's employment by, or provision of services to, the Company and its Affiliates, to the extent not already vested and exercisable, if the Participant's employment by, or provision of services to, the Company and its Affiliates terminates on account of the Participant's death or Disability.




(e)Method of Exercise and Payment for Shares. To the extent then vested and exercisable, the Participant may exercise the Option by delivering written notice of exercise, along with the exercise price for the portion of the Option being exercised, to the attention of the Company’s Secretary at the Company’s address specified in Section 8 below. Notwithstanding the foregoing, no single exercise of the Option may be for less than 100 shares of Common Stock unless, at the time of exercise, the maximum number of shares of Common Stock available for purchase under the Option is less than 100 shares, in which event the Option may be exercised, if at all, only for all of the shares of Common Stock then available for purchase. The exercise date shall be the date of the notice. The Participant shall pay the exercise price in cash or cash equivalent acceptable to the Committee. However, the Committee in its discretion may, but is not required to, allow the Participant to pay the exercise price (i) by surrendering shares of Common Stock the Participant already owns, (ii) by a cashless exercise through a broker, (iii) by means of a “net settlement” procedure, (iv) by such other medium of payment as the Committee shall authorize or (v) by any combination of the allowable methods of payment set forth herein. If payment is in the form of shares of Common Stock, then the certificate or certificates representing those shares must be duly executed in blank by the Participant or accompanied by a stock power duly executed in blank suitable for purposes of transferring those shares to the Company. Fractional shares of Common Stock will not be accepted in payment of the exercise price of the Option. The Company will not issue the shares of Common Stock until full payment of the exercise price for them has been made. As soon as administratively practicable upon the Company's receipt of the exercise price, subject to the other terms of the Option, the Company shall direct the issuance of the applicable shares of Common Stock so purchased. In the case of the Participant’s death, the Option, to the extent vested and exercisable, may be exercised by the executor or administrator of the Participant’s estate or by any person or persons who have acquired the Option directly from the Participant by bequest or inheritance.

(f)Non-Transferability of Option. The Participant shall not assign or transfer the Option, other than by will or the laws of descent and distribution. During the Participant’s lifetime, only the Participant (or, in the event of legal incapacity or incompetency, the Participant’s guardian or legal representative) may exercise the Option. Notwithstanding the foregoing, during the Participant’s lifetime, this Option may be transferred by the Participant to the Participant’s children, grandchildren, spouse, one or more trusts for the benefit of such family members or a partnership in which such family members are the only partners, on such terms and conditions as are appropriate for such transferees to be included in the class of transferees who may rely on a Form S-8 Registration Statement under the Securities Act of 1933 to sell shares issuable upon exercise of Options granted under the Plan. Any such transfer will be permitted only if (i) the Participant does not receive any consideration for the transfer and (ii) the Committee expressly approves the transfer. Any transferee to whom this Option is transferred shall be bound by the same terms and conditions that governed this Option during the time it was held by the Participant (which terms and conditions shall still be read from the perspective of the Participant); provided, however, that the transferee may not transfer this Option except by will or the laws of descent and distribution. Any such transfer shall be evidenced by an appropriate written document that the Participant executes and the Participant shall deliver a copy thereof to the Committee on or prior to the effective date of the transfer. No right or interest of the Participant or any transferee in this Option shall be liable for, or subject to, any lien, obligation or liability of the Participant or any transferee.

(g)Stock Holding Requirements. Notwithstanding any other provision of this Agreement, shares of Common Stock acquired pursuant to this Option may not be sold, transferred or otherwise disposed of until the level of ownership provided in the Company’s Stock Ownership Guidelines is met, to the extent applicable to the Participant. All shares of Common Stock acquired under the Plan (“net” shares acquired in case of any net exercise or withholding of shares) shall be subject to the




terms and conditions of the Company’s Stock Ownership Guidelines, as they may be amended from time to time.

3.    Termination of Option.

a.Exercise in the Event of Death, Disability or Retirement. This Option shall be exercisable for all or part of the number of shares of Common Stock that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant's employment by, or provision of services to, the Company and its Affiliates, reduced by the number of shares for which the Participant previously exercised the Option, to the extent the Participant’s rights have not otherwise been terminated under this Agreement, if the Participant's employment by, or provision of services to, the Company and its Affiliates terminates on account of the Participant's death, Disability or Retirement. In that event, this Option may be exercised by the Participant, the Participant’s estate, or the person or persons to whom the Participant’s rights under this Option shall pass by will or the laws of descent and distribution (to the extent applicable), for the remainder of the period preceding the Expiration Date or until the date that is twelve (12) months after the Participant’s Termination Date due to death, Disability or Retirement, whichever period is shorter.

b.Exercise after a Change of Control. This Option shall be exercisable for all or part of the number of shares of Common Stock that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant's employment by, or provision of services to, the Company and its Affiliates on or after a Change in Control, reduced by the number of shares for which the Participant previously exercised the Option, to the extent the Participant’s rights have not otherwise been terminated under this Agreement, if the Participant's employment by, or provision of services to, the Company and its Affiliates terminates on or after a Change in Control (other than as described in Section 3(a) above). In that event, the Participant may exercise this Option for the remainder of the period preceding the Expiration Date or until the date that is six (6) months after the Participant's Termination Date, whichever period is shorter.

c.Exercise after other Termination of Employment or Service. This Option shall be exercisable for all or part of the number of shares of Common Stock that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant's employment by, or provision of services to, the Company and its Affiliates, reduced by the number of shares for which the Participant previously exercised the Option, to the extent the Participant's rights have not otherwise terminated under this Agreement, if the Participant's employment by, or provision of services to, the Company and its Affiliates terminates other than under any of the circumstances set forth in Sections 3(a) or (b) of this Agreement, for the remainder of the period preceding the Expiration Date or until the date that is three (3) months after the Participant's Termination Date, whichever period is shorter.

d.Termination. The Option or portion thereof not either terminated or exercised at such time will terminate automatically and without further notice at the time the Option can no longer be exercised as set forth above.

e.For Cause. Notwithstanding any other provision of this Agreement, the Option will terminate automatically upon the termination of the Participant's employment by, or provision of services to, the Company and its Affiliates for Cause, immediately upon notice of such termination (including any portion of the Option that may have become vested and exercisable previously).





4.    Agreement to Terms of the Plan and Agreement. The Participant has received a copy of the Plan, has read and understands the terms of the Plan and this Agreement, and agrees to be bound by their terms and conditions. All decisions and interpretations made by the Company or the Committee with regard to any question arising under this Option will be binding and conclusive on the Company and the Participant and any other person entitled to exercise the Options as provided for in this Agreement.

5.    Tax Consequences. The Participant acknowledges (i) that there may be adverse tax consequences upon acquisition or disposition of the shares of Common Stock received upon exercise of this Option and (ii) that Participant should consult a tax adviser prior to such acquisition or disposition. The Participant is solely responsible for determining the tax consequences of the Option and for satisfying the Participant’s tax obligations with respect to the Option (including, but not limited to, any income or excise tax as resulting from the application of Code Sections 409A or 4999 or related interest and penalties), and the Company and its Affiliates shall not be liable if this Option is subject to Code Sections 409A, 280G or 4999. The Company’s obligation to deliver shares of Common Stock upon exercise of the Option is subject to the Participant’s satisfaction of any applicable federal, state and local income and employment tax and withholding requirements in a manner and form satisfactory to the Company. The Committee, to the extent applicable law permits, may allow the Participant to pay any such amounts (but only for the minimum required withholding or such other amounts as will not otherwise have negative accounting consequences) (i) by surrendering (actual or by attestation) shares of Common Stock that the Participant already owns; (ii) by a cashless exercise though a broker, (iii) by means of a “net exercise” procedure or (iv) by such other medium of payment as the Committee in its discretion shall authorize.

6.    Fractional Shares. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle the Participant to a fractional share such fractional share shall be disregarded.

7.    Change in Capital Structure. The terms of this Option shall be adjusted in accordance with the terms and conditions of the Plan as the Committee determines is equitably required in the event the Company effects one or more stock dividends, stock splits, subdivisions or consolidations of shares or other similar changes in capitalization.

8.    Notice. Any notice or other communication given pursuant to this Agreement, or in any way with respect to this Option, shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the following addresses:

If to the Company:    MiMedx Group, Inc.
1775 West Oak Commons Ct. NE
Marietta, Georgia 30062
Attn: ___________________

If to the Participant:    _____________________________
_____________________________
_____________________________


9.    Shareholder Rights. The Participant shall not have any rights as a shareholder with respect to shares of Common Stock subject to this Option until the issuance of the shares of the Common Stock upon exercise of the Option.

10.    No Right to Continued Employment or Service. Neither the Plan, the granting of this Option nor any other action taken pursuant to the Plan or this Option constitutes or is evidence of any




agreement or understanding, expressed or implied, that the Company or any Affiliate shall retain the Participant as an employee or other service provider for any period of time or at any particular rate of compensation.

11.    Binding Effect. Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of the Participant and the successors of the Company.

12.    Conflicts. In the event of any conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall govern. All references herein to the Plan shall mean the Plan as in effect on the date hereof.

13.    Counterparts. This Agreement may be executed in a number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one in the same instrument.

14.    Miscellaneous. The parties agree to execute such further instruments and take such further actions as may be necessary to carry out the intent of the Plan and this Agreement. This Agreement and the Plan shall constitute the entire agreement of the parties with respect to the subject matter hereof.

15.    Section 409A. Notwithstanding any of the provisions of this Agreement, it is intended that the Option be exempt from Section 409A of the Code. Notwithstanding the preceding, neither the Company nor any Affiliate shall be liable to the Participant or any other person if the Internal Revenue Service or any court or other authority have any jurisdiction over such matter determines for any reason that the Option is subject to taxes, penalties or interest as a result of failing to be exempt from, or comply with, Section 409A of the Code.

16.    Compensation Recoupment Policy. Notwithstanding any other provision of this Agreement, the Participant shall reimburse or return to the Company the gross number of shares of Common Stock that the Participant received (or would have received absent a “net exercise” procedure) under this Agreement or, if greater, the amount of gross proceeds from any earlier sale of any such shares of Common Stock, plus any other amounts received with respect to this Award, to the extent any reimbursement, recoupment or return is required under applicable law or the Company’s Compensation Recoupment Policy or any similar policy that the Company may adopt.

17.    Governing Law. This Agreement shall be governed by the governing laws applicable to the Plan.

[Signatures continued on next page]
















IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and the Participant has affixed the Participant’s signature hereto.

COMPANY:
MIMEDX GROUP, Inc.
By:    ___________________________________
Name:    ___________________________________
Title:    ___________________________________
PARTICIPANT:
____________________________________
[Participant’s Name]




 EX-31.1 5 exhibit311-certificationof.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Parker H. Petit, certify that:
 
1. I have reviewed this Form 10-Q for the quarter ended June 30, 2016, of MiMedx Group, Inc.;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
August 2, 2016
/s/ Parker H. Petit
 
 
Parker H. Petit
 
 
Chief Executive Officer


 EX-31.2 6 exhibit312-certificationof.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Michael J. Senken, certify that:

1. I have reviewed this Form 10-Q for the quarter ended June 30, 2016, of MiMedx Group, Inc.;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer  and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
August 2, 2016
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer


 EX-32.1 7 exhibit321-certificationof.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Parker H. Petit, Chief Executive Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
August 2, 2016
/s/ Parker H. Petit
 
 
Parker H. Petit
 
 
Chief Executive Officer


 EX-32.2 8 exhibit322-certificationof.htm EXHIBIT 32.2 Exhibit


 Exhibit 32.2
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Senken, Chief Financial Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
August 2, 2016
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer


 EX-101.INS 9 mdxg-20160630.xml XBRL INSTANCE DOCUMENT 0001376339 2016-01-01 2016-06-30 0001376339 2016-07-15 0001376339 2015-12-31 0001376339 2016-06-30 0001376339 2015-01-01 2015-06-30 0001376339 2015-04-01 2015-06-30 0001376339 2016-04-01 2016-06-30 0001376339 us-gaap:RetainedEarningsMember 2016-01-01 2016-06-30 0001376339 us-gaap:TreasuryStockMember 2016-06-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-06-30 0001376339 us-gaap:TreasuryStockMember 2016-01-01 2016-06-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001376339 us-gaap:CommonStockMember 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2016-06-30 0001376339 us-gaap:CommonStockMember 2016-06-30 0001376339 us-gaap:CommonStockMember 2016-01-01 2016-06-30 0001376339 us-gaap:TreasuryStockMember 2015-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0001376339 2014-12-31 0001376339 2015-06-30 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2016-01-13 2016-01-13 0001376339 us-gaap:PatentsMember 2016-01-01 2016-06-30 0001376339 us-gaap:PatentsMember 2015-01-01 2015-06-30 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2016-01-01 2016-06-30 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember 2016-06-30 0001376339 us-gaap:ProFormaMember 2015-01-01 2015-06-30 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2015-01-01 2015-06-30 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LineOfCreditMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LoansPayableMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember mdxg:ShareholderDebtMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:TrademarksAndTradeNamesMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 2016-01-13 0001376339 us-gaap:CertificatesOfDepositMember 2015-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2016-06-30 0001376339 us-gaap:ConstructionInProgressMember 2016-06-30 0001376339 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001376339 us-gaap:ConstructionInProgressMember 2015-12-31 0001376339 us-gaap:EquipmentMember 2015-12-31 0001376339 us-gaap:EquipmentMember 2016-06-30 0001376339 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2016-06-30 0001376339 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-06-30 0001376339 mdxg:LeaseholdImprovementsPaidbyOthersMember 2016-06-30 0001376339 mdxg:PatentsinProcessMember 2016-06-30 0001376339 mdxg:TradeNamesAndTrademarksMember 2016-06-30 0001376339 us-gaap:CustomerRelationshipsMember 2016-06-30 0001376339 us-gaap:NoncompeteAgreementsMember 2016-01-01 2016-06-30 0001376339 mdxg:PatentsinProcessMember 2015-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2015-12-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2016-06-30 0001376339 us-gaap:LicensingAgreementsMember 2015-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2016-01-01 2016-06-30 0001376339 us-gaap:LicensingAgreementsMember 2016-01-01 2016-06-30 0001376339 us-gaap:PatentsMember 2016-06-30 0001376339 us-gaap:NoncompeteAgreementsMember 2015-12-31 0001376339 mdxg:TradeNamesAndTrademarksMember 2015-12-31 0001376339 us-gaap:PatentsMember 2015-12-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001376339 us-gaap:LicensingAgreementsMember 2016-06-30 0001376339 us-gaap:NoncompeteAgreementsMember 2016-06-30 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-28 2007-01-29 0001376339 mdxg:SurgicalBiologicsMember us-gaap:CustomerRelationshipsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:LicensingAgreementsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2016-01-01 2016-06-30 0001376339 mdxg:SurgicalBiologicsMember mdxg:TradeNamesAndTrademarksMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:InProcessResearchAndDevelopmentMember 2011-01-05 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-29 0001376339 mdxg:StabilityBiologicsLLCMember mdxg:TradeNamesAndTrademarksMember 2016-01-13 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2016-06-30 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 2015-10-12 0001376339 us-gaap:WarrantMember 2016-04-01 2016-06-30 0001376339 us-gaap:WarrantMember 2015-04-01 2015-06-30 0001376339 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0001376339 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001376339 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 0001376339 us-gaap:RestrictedStockMember 2016-01-01 2016-06-30 0001376339 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0001376339 us-gaap:WarrantMember 2015-01-01 2015-06-30 0001376339 us-gaap:RestrictedStockMember 2016-04-01 2016-06-30 0001376339 us-gaap:RestrictedStockMember 2015-01-01 2015-06-30 0001376339 us-gaap:RestrictedStockMember 2015-04-01 2015-06-30 0001376339 us-gaap:WarrantMember 2016-01-01 2016-06-30 0001376339 us-gaap:RestrictedStockMember 2016-01-01 2016-06-30 0001376339 us-gaap:RestrictedStockMember 2016-06-30 0001376339 us-gaap:RestrictedStockMember 2015-12-31 0001376339 2014-05-12 0001376339 mdxg:PriceRange7Member 2016-01-01 2016-06-30 0001376339 mdxg:PriceRange2Member 2016-06-30 0001376339 mdxg:PriceRange4Member 2016-06-30 0001376339 mdxg:PriceRange7Member 2016-06-30 0001376339 mdxg:PriceRange5Member 2016-06-30 0001376339 mdxg:PriceRange3Member 2016-06-30 0001376339 mdxg:PriceRange6Member 2016-06-30 0001376339 mdxg:PriceRange5Member 2016-01-01 2016-06-30 0001376339 mdxg:PriceRange2Member 2016-01-01 2016-06-30 0001376339 mdxg:PriceRange1Member 2016-01-01 2016-06-30 0001376339 mdxg:PriceRange3Member 2016-01-01 2016-06-30 0001376339 mdxg:PriceRange1Member 2016-06-30 0001376339 mdxg:PriceRange4Member 2016-01-01 2016-06-30 0001376339 mdxg:PriceRange6Member 2016-01-01 2016-06-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-04-01 2015-06-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-06-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-06-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-04-01 2016-06-30 0001376339 us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001376339 us-gaap:CostOfSalesMember 2015-04-01 2015-06-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0001376339 us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0001376339 us-gaap:CostOfSalesMember 2015-01-01 2015-06-30 0001376339 2015-01-01 2015-12-31 0001376339 2016-01-01 2016-03-31 0001376339 us-gaap:ScenarioForecastMember 2016-01-01 2016-12-31 0001376339 mdxg:LiventaActionMember us-gaap:PendingLitigationMember 2015-12-22 0001376339 mdxg:LiventaAction437PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 mdxg:LiventaActionMember us-gaap:PendingLitigationMember 2015-12-30 0001376339 us-gaap:PendingLitigationMember 2016-06-30 0001376339 mdxg:LiventaAction701PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-06-29 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-07-10 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-10-02 0001376339 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2015-01-01 2015-12-31 0001376339 us-gaap:StandbyLettersOfCreditMember 2016-06-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-04-01 2016-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-04-01 2016-06-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-06-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2015-04-01 2015-06-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-06-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-04-01 2015-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2015-03-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-01-01 2015-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-03-31 0001376339 mdxg:AllowanceforObsolescenceMember 2016-01-01 2016-06-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-04-01 2016-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-06-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-04-01 2015-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2014-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2016-03-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-06-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-03-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-03-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-01-01 2015-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2015-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-01-01 2016-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-03-31 iso4217:USD xbrli:shares mdxg:plan xbrli:pure mdxg:segment iso4217:USD mdxg:term mdxg:claim xbrli:shares false --12-31 Q2 2016 2016-06-30 10-Q 0001376339 110042283 Large Accelerated Filer MIMEDX GROUP, INC. 2001000 28000 2179000 -4515000 408000 0.12 0.03 0.03 350000 0.31 4864000 6122000 35000000 1 2 30 1 1 4 402000 327000 P30D 12000 308000 0 6633000 9678000 53755000 54861000 4644000 6988000 4979000 6728000 P13Y P7Y P4Y P19Y 163133000 156457000 684000 684000 4255000 90000 203000 3962000 8186000 184000 389000 7613000 4503000 95000 155000 4253000 9124000 190000 360000 8574000 0 91000 233000 465000 787000 447000 1257000 7975209 7411271 526029 37909 7878335 7393698 446929 37708 5956483 5644128 312355 0 6221324 5805870 415454 0 135913000 177055000 96310000 101841000 441009 0.04 0.07 0.02 0.03 9.07 4919000 7975000 1224000 2057000 3668000 50492000 96413000 57342000 111258000 851000 851000 36257000 3346000 1771000 25620000 200000 25620000 0 9642000 0 15978000 -480000 140000 100000 8815000 194000 8268000 830000 17860000 6090000 690000 1080000 9170000 8725000 85000 932000 560000 199000 1375000 36257000 46582000 38601000 28486000 23803000 -7981000 -4683000 0.001 0.001 150000000 150000000 109467416 110025697 107361471 110022283 109000 110000 0.12 10500000 644000 1366000 3310000 3128000 2052000 5089000 10237000 7394000 15341000 0.0225 0.015 P3Y 487000 444000 500000 14838000 7077000 422000 776000 821000 1555000 0.05 0.09 0.02 0.03 0.05 0.08 0.02 0.03 0.037 0.347 0.422 15034000 10245000 P2Y1M6D 24939716 3283152 P12Y P2Y P4Y P20Y 16223000 1259000 1802000 2072000 2072000 2427000 3761000 1009000 0 8001000 9851000 1699000 1080000 17176000 3761000 13000 7690000 6090000 690000 1080000 9170000 25855000 402000 327000 4000 4040000 26951000 22912000 40590000 76209000 49948000 95369000 5653000 9886000 3450000 4861000 223000 369000 1475000 1689000 874000 631000 2060000 -5597000 12776000 -894000 1221000 2344000 -1862000 -4789000 2000000 -1274000 2245000 800000 26000 264000 -586000 1318000 1106000 1781000 1823000 1008000 25000 2146000 1838000 25000 1008000 25000 830000 15627000 33815000 10763000 27693000 29000 76000 3405000 11945000 7857000 18987000 7460000 17207000 602000 1154000 397000 1780000 3850000 5888000 0 1224000 1200000 310000 593000 436000 859000 P8Y 118000 27925000 55450000 135913000 177055000 26777000 38538000 0 50000000 4 7 7 6 5 -13959000 -2273000 -1165000 -8713000 7143000 6303000 5430000 9517000 1975000 3172000 3172000 1 5652000 9899000 3561000 5028000 466000 1985000 1148000 934000 72000 1000 -13000 -111000 -167000 3518000 0 61000 0 684000 6000000 6000000 0 7631000 59000 14000 996000 2513000 3755000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 3609000 5970000 -16641000 -3530000 1750000 3000000 2741000 2016000 14454000 2629000 4564000 4577000 2684000 19777000 2169000 8196000 6167000 3245000 9475000 13049000 1000000 427000 2054000 3885000 3168000 5664000 -38130000 -34958000 50000 45679000 86446000 57342000 110710000 32651000 61960000 42772000 83420000 8186000 9124000 102230 8.85 2014838 8.04 2613267 3700280 9.14 8.66 825595 8.63 0 0.581 0.544 0.0168 0.0151 13047941 3.27 4937922 29191 79810 0 56844050 14019629 13106587 3.62 3.67 56809041 11710880 3.66 2.51 6.44 6.44 0.00 0.50 0.87 1.40 2.66 4.19 6.45 9.90 11730880 441429 4420470 1458424 889430 2898133 1586502 36492 13106587 441429 4420470 1458424 889430 3310253 2479415 107166 0.76 1.35 2.45 3.99 6.38 9.78 10.99 P6Y 55362178 P5Y9M18D P6Y 3.27 0.72 1.19 1.92 3.06 5.28 7.23 10.44 3.67 0.72 1.19 1.92 3.06 5.36 7.29 10.43 P6Y P2Y10M24D P5Y2M12D P4Y4M24D P6Y3M18D P6Y10M24D P7Y7M6D P8Y4M24D 109467416 2105945 110025697 3414 81594 3000000 3000000 0 441009 -441009 11321 20406 -20406 102230 334353 -1660079 804041 223928 -580113 2599377 0 3346000 -462000 3808000 108000 173000 4000 169000 0 -825000 825000 0 -13422000 1000 13421000 9124000 9124000 2016000 -2745000 4761000 21334000 20000000 60000000 10000000 10756000 107988000 163133000 109000 -38130000 -17124000 121605000 156457000 110000 -34958000 -4000 2105945 3414 415252 415252 17124000 4000 3530000 3530000 -15400000 527000 1750000 841000 552000 2010000 944000 553000 2504000 1030000 397000 3270000 1262000 604000 3872000 1708000 1780000 4086000 2191000 90000 500000 734000 221000 760000 1443000 1335000 233000 2106000 1570000 835000 3467000 89000 6000 648000 195000 6000 1254000 159000 19000 1623000 187000 19000 2538000 7975209 7878335 5956483 6221324 114186329 113892087 112148415 112095051 106211120 106013752 106191932 105873727 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Management&#8217;s Plans</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$23,803,000</font><font style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents.&#160;&#160;The Company reported total current assets of approximately </font><font style="font-family:inherit;font-size:10pt;">$101,841,000</font><font style="font-family:inherit;font-size:10pt;"> and current liabilities of approximately </font><font style="font-family:inherit;font-size:10pt;">$38,538,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (a) (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents &amp; Know How (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer &amp; Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames &amp; Trademarks (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,838</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Process Research &amp; Development (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,815</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,627</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Accumulated amortization and impairment charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.&#160;&#160;Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.&#160;&#160;As a result, the Company recorded intangible assets for Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research &amp; Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. For the six months ended June 30, 2016, approximately </font><font style="font-family:inherit;font-size:10pt;">$4,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents &amp; Know-How subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents &amp; Know-How under intangible assets subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents &amp; Know - How of </font><font style="font-family:inherit;font-size:10pt;">$9,170,000</font><font style="font-family:inherit;font-size:10pt;">, Customer Relationships of </font><font style="font-family:inherit;font-size:10pt;">$6,090,000</font><font style="font-family:inherit;font-size:10pt;">, Non - compete agreements of</font><font style="font-family:inherit;font-size:10pt;">$1,080,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$830,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$690,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;&#160;Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of Accounting Standards Updates (&#8220;ASU&#8217;&#8217;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;).&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;&#160;Operating results for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.&#160;&#160;The balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unaudited pro forma information for the three and six months ended June 30, 2016 and 2015 (in thousands) is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:627px;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:225px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per share, fully diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition of Stability Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6,000,000</font><font style="font-family:inherit;font-size:10pt;"> cash, </font><font style="font-family:inherit;font-size:10pt;">$3,346,000</font><font style="font-family:inherit;font-size:10pt;"> in stock, represented by </font><font style="font-family:inherit;font-size:10pt;">441,009</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and assumed debt of </font><font style="font-family:inherit;font-size:10pt;">$1,771,000</font><font style="font-family:inherit;font-size:10pt;">. Additional one time costs incurred in connection with the transaction totaled </font><font style="font-family:inherit;font-size:10pt;">$851,000</font><font style="font-family:inherit;font-size:10pt;"> and are included withing selling, general and administrative expenses on the condensed consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of June 30, 2016, the contingent consideration was valued at </font><font style="font-family:inherit;font-size:10pt;">$25,620,000</font><font style="font-family:inherit;font-size:10pt;"> and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument,</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">predominantly on variations in something other than the fair value of the issuer&#8217;s equity shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">associated with the combination. The actual purchase price has been preliminarily allocated as of June 30, 2016 (in</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thousands) and is subject to change:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:602px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:458px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued (441,009 shares valued at $9.07 per share)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn-out</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital and other assets were composed of the following (in thousands):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid Expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,725</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of Credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder loan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - Business Combinations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recorded at fair value on the acquisition date and will be remeasured quarterly until purchase accounting is completed based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization.The intangible assets were assigned the following lives for amortization purposes:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:603px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:458px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated useful life (in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name and Trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the transaction and is preliminary as of June 30, 2016 and is subject to change. Goodwill is tested for impairment on an annual basis as definedby FASB Topic 350 - "Intangibles - Goodwill and Other".</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma summary financial information presents the consolidated results of operations as if the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the results that may occur in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unaudited pro forma information for the three and six months ended June 30, 2016 and 2015 (in thousands) is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:627px;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:225px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per share, fully diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 supplemental pro forma earnings were adjusted to exclude </font><font style="font-family:inherit;font-size:10pt;">$851,000</font><font style="font-family:inherit;font-size:10pt;"> of acquisition-related legal, audit and other</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include </font><font style="font-family:inherit;font-size:10pt;">$787,000</font><font style="font-family:inherit;font-size:10pt;"> of amortization costs related to</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recorded intangible assets with defined useful lives, and </font><font style="font-family:inherit;font-size:10pt;">$1,224,000</font><font style="font-family:inherit;font-size:10pt;"> of inventory step-up charges as a result of the acquisition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include </font><font style="font-family:inherit;font-size:10pt;">441,009</font><font style="font-family:inherit;font-size:10pt;"> shares issued as part of the purchase price and assumed to be issued on January 1, 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short Term Investments</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short term investments consisted of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of cash flow and non-cash investing and financing activities:</font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">874</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 441,009 shares in connection with acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Commitments</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next </font><font style="font-family:inherit;font-size:10pt;">eight years</font><font style="font-family:inherit;font-size:10pt;"> and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12-month period ended June 30</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,128</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,366</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$859,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$593,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and was approximately </font><font style="font-family:inherit;font-size:10pt;">$436,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$310,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Letters of Credit</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$118,000</font><font style="font-family:inherit;font-size:10pt;">. These obligations are reduced at various times over the life of the lease.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Untitled Letter and Draft Guidance</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (&#8220;BLA&#8221;) process for certain of its micronized products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2014, the FDA issued for comment &#8220;Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.&#8221; Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA&#8217;s statutory authority, is inconsistent with existing HCT/P regulations and the FDA&#8217;s prior positions, and is internally inconsistent and scientifically unsound. On&#160;October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has indicated that it will hold a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The hearing was originally scheduled for April 13, 2016, but was rescheduled to September 2016 in order to allow stakeholders additional time to provide comments due to the considerable interest in the hearing. The Company has requested, and has been granted, an opportunity to speak at the rescheduled hearing. The FDA has also scheduled a related scientific workshop to be held prior to the hearing to identify and discuss the scientific considerations and challenges to help inform the development of HCT/Ps.</font></div><div style="line-height:120%;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">&#160;of the Company's revenues for the fiscal year ended December 31, 2015.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Litigation</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> actions pending, as described below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Liventa Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Norther District of Georgia against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached an amicable settlement of the False Advertising Claims for an undisclosed sum. The patent infringement claims are still pending as described below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the &#8217;437 and &#8217;687 Patents, seeking a partial stay of the litigation as to the &#8217;437, &#8217;687, and &#8217;494 Patents (i.e., the &#8217;437 Patent family). MiMedx opposed the Motion to Stay with respect to the &#8217;494 Patent and once again successfully defeated Defendants&#8217; motion to stay.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2015, a Markman Hearing was held before a Special Master. Over </font><font style="font-family:inherit;font-size:10pt;">thirty</font><font style="font-family:inherit;font-size:10pt;"> disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> term, the Special Master&#8217;s Report essentially adopted MiMedx&#8217;s proposed constructions. On March 9, 2016, the Court adopted the Special Master&#8217;s Report. Since then the Court has entered a scheduling order in this action. Fact discovery has closed and the parties are currently engaging in expert discovery, which is expected to close in early September 2016. We expect the case to go to trial in late 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Bone Bank Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, Defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. The Markman hearing in this case was held on October 2, 2015. Except for </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> term, the Court adopted MiMedx&#8217;s proposed construction of the disputed terms. Fact discovery has closed and the parties are currently engaging in expert discovery, which is expected to close in August 2016. We expect the case to go to trial in the fall of 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The NuTech Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On November 24, 2015, the court ruled on NuTech&#8217;s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement, as well as violations of the Lanham Act which are still pending.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, the parties submitted their Initial Disclosures, and MiMedx submitted its preliminary infringement contentions. On March 14, 2016, Defendants submitted their preliminary invalidity contentions. On April 15, 2016, the parties exchanged proposed terms for construction and over the next several months the parties will engage in claim construction briefing and related proceedings. Discovery is ongoing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;"> The Vivex Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (&#8220;Vivex&#8221;) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "494" patent). Vivex answered MiMedx&#8217;s Complaint and filed Counterclaims of noninfringement and invalidity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pending IPRs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "687" patent) and the 494 patent; while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> challenged grounds. The parties decided to forego oral arguments. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment not configuration, were invalid for obviousness. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> challenged grounds. A decision is expected no later than August of 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12-month period ended June 30</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,128</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,366</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">. The Credit Agreement also provides for an uncommitted incremental facility of up to </font><font style="font-family:inherit;font-size:10pt;">$35 million</font><font style="font-family:inherit;font-size:10pt;">, which can be</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid in connection with the initiation of the credit facility totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">. These deferred financing costs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">are being amortized to interest expense over the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year life of the facility. The Credit Agreement contains customary</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">representations, warranties, covenants, and events of default. As of June 30, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> outstanding revolving loans</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">under the credit facility.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Incentive Plans</font><font style="font-family:inherit;font-size:10pt;">&#160; </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> share-based compensation plans: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016, the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the &#8220;Assumed 2006 Plan&#8221;), the MiMedx Inc. 2007 Assumed Stock Plan (the &#8220;Assumed 2007 Plan&#8221;) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the &#8220;Assumed 2005 Plan&#8221;) which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2016 Plan to make future grants. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(804,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79,810</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,106,587</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,844,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,710,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,362,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at June 30, 2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,047,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,809,041</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of the options exercised during the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$4,937,922</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,420,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,420,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,310,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,898,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45 - $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,479,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,586,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90- $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,166</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,106,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,730,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized compensation expense related to granted stock options at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,283,152</font><font style="font-family:inherit;font-size:10pt;"> and will be charged to expense ratably through May 2018.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.&#160;&#160;Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.&#160;&#160;The term of employee options granted is derived using the &#8220;simplified method,&#8221; which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.&#160;&#160;The term for non-employee options is generally based upon the contractual term of the option.&#160;&#160;The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54.4 - 58.1 %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51% - 1.68%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> options granted during the six months ended June 30, 2016.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to restricted stock awards is summarized as follows:&#160; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.14</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,014,838</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.04</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(825,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.63</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.85</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,700,280</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.66</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$24,939,716</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.&#160;&#160;That expense is expected to be recognized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.1</font><font style="font-family:inherit;font-size:10pt;"> years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized stock-based compensation as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,253</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,962</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,574</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,613</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,255</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On May 12, 2014, our Board of Directors authorized the repurchase of up to </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> and further increased the authorization in 2015 to </font><font style="font-family:inherit;font-size:10pt;">$60 million</font><font style="font-family:inherit;font-size:10pt;">. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">415,252</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for a purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,518,000</font><font style="font-family:inherit;font-size:10pt;"> before brokerage commissions of approximately </font><font style="font-family:inherit;font-size:10pt;">$12,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$10,756,000</font><font style="font-family:inherit;font-size:10pt;"> of availability remaining under the repurchase program.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company reissued </font><font style="font-family:inherit;font-size:10pt;">2,599,377</font><font style="font-family:inherit;font-size:10pt;"> shares from the Treasury for restricted stock grants and stock option exercises, net of forfeitures, and as partial consideration to the shareholders of Stability, with an aggregate carrying value of approximately </font><font style="font-family:inherit;font-size:10pt;">$21,334,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income (Loss) Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.&#160;&#160;Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,191,932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,211,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,873,727</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,013,752</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,956,483</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,975,209</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,221,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,878,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,148,415</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,186,329</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,095,051</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,892,087</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.09</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.08</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,644,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,411,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,805,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,393,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,956,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,975,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,221,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,878,335</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intangible assets were assigned the following lives for amortization purposes:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:603px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:458px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated useful life (in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name and Trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effective tax rates for continuing operations of&#160;</font><font style="font-family:inherit;font-size:10pt;">34.7%</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">3.7%</font><font style="font-family:inherit;font-size:10pt;"> for the six months ended June 30, 2016 and June 30, 2015, respectively, were determined using an estimated annual effective tax rate and include, in 2016, the impact of a discrete item of approximately </font><font style="font-family:inherit;font-size:10pt;">$350,000</font><font style="font-family:inherit;font-size:10pt;">. The effective tax rate for the 2016 period increased approximately </font><font style="font-family:inherit;font-size:10pt;">31%</font><font style="font-family:inherit;font-size:10pt;"> when compared to the same period of 2015, primarily due to the </font><font style="font-family:inherit;font-size:10pt;">$15.4 million</font><font style="font-family:inherit;font-size:10pt;"> valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the six months ended June 30, 2015, did not include the expense of the current period U.S. taxable income. As of the end of June 2016, the projected annual effective tax rate for 2016 is </font><font style="font-family:inherit;font-size:10pt;">42.2%</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Royalty Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (a) (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents &amp; Know How (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer &amp; Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames &amp; Trademarks (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,838</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Process Research &amp; Development (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,815</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,627</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Accumulated amortization and impairment charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.&#160;&#160;Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.&#160;&#160;As a result, the Company recorded intangible assets for Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research &amp; Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. For the six months ended June 30, 2016, approximately </font><font style="font-family:inherit;font-size:10pt;">$4,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents &amp; Know-How subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents &amp; Know-How under intangible assets subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents &amp; Know - How of </font><font style="font-family:inherit;font-size:10pt;">$9,170,000</font><font style="font-family:inherit;font-size:10pt;">, Customer Relationships of </font><font style="font-family:inherit;font-size:10pt;">$6,090,000</font><font style="font-family:inherit;font-size:10pt;">, Non - compete agreements of</font><font style="font-family:inherit;font-size:10pt;">$1,080,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$830,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$690,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$1,257,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$465,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$447,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$233,000</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">three months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending&#160;December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,223</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,945</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,405</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,987</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,780</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of June 30, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately </font><font style="font-family:inherit;font-size:10pt;">$800,000</font><font style="font-family:inherit;font-size:10pt;">, which is comprised of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of the date of the acquisition less amortization of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the six months ended June 30, 2016. Please see Note 4 contained herein.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not yet effective. In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue Recognition - Revenue from Contracts with</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customers&#8221; (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, 'Balance Sheet Classification of Deferred Taxes'. ASU 2015-17</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, 'Leases (Topic 842)'. The core principle of Topic 842 is that a lessee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the six months ended June 30, 2016, and through the date of this report,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;&#160;Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of Accounting Standards Updates (&#8220;ASU&#8217;&#8217;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;).&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;&#160;Operating results for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.&#160;&#160;The balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix&#174; and EpiFix&#174;, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology, CollaFix&#8482;, which the Company has yet to commercialize. Through the recent acquisition of Stability Inc., our newest proprietary platforms include Physio&#174;, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn&#8482;, a skin product for burns.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Property and equipment consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,196</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,169</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,728</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,979</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,049</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in net property and equipment is approximately </font><font style="font-family:inherit;font-size:10pt;">$427,000</font><font style="font-family:inherit;font-size:10pt;"> of equipment covered under capital leases. The corresponding liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$72,000</font><font style="font-family:inherit;font-size:10pt;"> is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;"> with maturity dates from September 2016 to January 2018.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also included is approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$1,555,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$776,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and approximately </font><font style="font-family:inherit;font-size:10pt;">$821,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$422,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,196</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,169</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,728</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,979</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,049</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.&#160;&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price has been preliminarily allocated as of June 30, 2016 (in</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thousands) and is subject to change:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:602px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:458px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued (441,009 shares valued at $9.07 per share)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn-out</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital and other assets were composed of the following (in thousands):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid Expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,725</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of Credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder loan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">874</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 441,009 shares in connection with acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,191,932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,211,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,873,727</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,013,752</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,956,483</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,975,209</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,221,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,878,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,148,415</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,186,329</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,095,051</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,892,087</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.09</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.08</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,644,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,411,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,805,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,393,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,956,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,975,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,221,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,878,335</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized stock-based compensation as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,253</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,962</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,574</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,613</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,255</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,945</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,405</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,987</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,780</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,420,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,420,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,310,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,898,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45 - $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,479,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,586,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90- $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,166</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,106,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,730,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(804,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79,810</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,106,587</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,844,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,710,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,362,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at June 30, 2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,047,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,809,041</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54.4 - 58.1 %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51% - 1.68%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to restricted stock awards is summarized as follows:&#160; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.14</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,014,838</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.04</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(825,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.63</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.85</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,700,280</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.66</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Schedule II Valuation and Qualifying Accounts</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MIMEDX GROUP, INC. AND SUBSIDIARIES</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS</font></div></td></tr><tr><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Three and Six Months Ended June 30, 2016 and 2015 (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at <br clear="none"/>Beginning of Period</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions charged to Expense or Revenue</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions <br clear="none"/>and write-offs</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at<br clear="none"/> End of Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,623</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended June 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the six months ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,467</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,538</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the six months ended June 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending&#160;December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,223</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix&#174; and EpiFix&#174;, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology, CollaFix&#8482;, which the Company has yet to commercialize. Through the recent acquisition of Stability Inc., our newest proprietary platforms include Physio&#174;, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn&#8482;, a skin product for burns. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see Note 2 to the Company's Consolidated Financial Statements included in the Company&#8217;s Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, for a description of all significant accounting policies.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of June 30, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately </font><font style="font-family:inherit;font-size:10pt;">$800,000</font><font style="font-family:inherit;font-size:10pt;">, which is comprised of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of the date of the acquisition less amortization of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the six months ended June 30, 2016. Please see Note 4 contained herein.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately </font><font style="font-family:inherit;font-size:10pt;">$327,000</font><font style="font-family:inherit;font-size:10pt;"> of patent costs during the first six months of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The Company capitalized approximately </font><font style="font-family:inherit;font-size:10pt;">$402,000</font><font style="font-family:inherit;font-size:10pt;"> of patent costs during the first six months of 2015.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not yet effective. In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue Recognition - Revenue from Contracts with</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customers&#8221; (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, 'Balance Sheet Classification of Deferred Taxes'. ASU 2015-17</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, 'Leases (Topic 842)'. The core principle of Topic 842 is that a lessee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the six months ended June 30, 2016, and through the date of this report,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div></div> EX-101.SCH 10 mdxg-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - Acquisition of Stability Inc. link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Acquisition of Stability Inc. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Acquisition of Stability Inc. - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Acquisition of Stability Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Contractual Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Contractual Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Credit Facility link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Equity - Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Equity - Stock Incentive Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Equity - Treasury Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Intangible Assets and Royalty Agreement link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Intangible Assets and Royalty Agreement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Liquidity and Management's Plans link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Liquidity and Management's Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Schedule - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2417401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Short Term Investments link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Short Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 mdxg-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 mdxg-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 mdxg-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Earnings Per Share [Abstract] Net Income (Loss) Per Share Earnings Per Share [Text Block] Valuation and Qualifying Accounts [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Allowance for doubtful accounts Allowance for Doubtful Accounts [Member] Allowance for product returns Allowance for Sales Returns [Member] Allowance for obsolescence Allowance for Obsolescence [Member] Allowance for Obsolescence [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Movement in Valuation Allowances and Reserves [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Period Valuation Allowances and Reserves, Balance Additions charged to Expense or Revenue Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Deductions and write-offs Valuation Allowances and Reserves, Deductions Balance at End of Period Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Tax Contingency [Table] Income Tax Contingency [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Forecast Scenario, Forecast [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Effective income tax rate increase (decrease), amount Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Amount Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Amount Effective income tax rate increase (decrease), percent Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Percent Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Percent Decrease in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Liquidity and management's plans [Abstract] -- None. No documentation exists for this element. -- Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Total current liabilities Liabilities, Current Document and Entity Information [Abstract] -- None. No documentation exists for this element. -- Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Amendment Flag Document Period End Date Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, general and administrative Selling, General and Administrative Expenses [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Stability Biologics, LLC Stability Biologics, LLC [Member] Stability Biologics, LLC Pro Forma Pro Forma [Member] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Fair Value Adjustment to Inventory Fair Value Adjustment to Inventory [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Cash paid at closing Payments to Acquire Businesses, Gross Common stock issued Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Common stock issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Assumed debt Business Combination, Consideration Transferred, Liabilities Incurred Acquisition related costs Business Combination, Acquisition Related Costs Fair value of earn-out Business Combination, Contingent Consideration, Liability Amortization of intangible assets Amortization of Intangible Assets Net income Business Acquisition, Pro Forma Net Income (Loss) Liquidity and Management's Plans Liquidity and management's plans [Text Block] The entire disclosure of management's assessment of funding needs and access to credit facilities to meet cash operational needs in the long term. Debt Disclosure [Abstract] Credit Facility Debt Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Computation of Basic and Diluted Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of basic and diluted net loss per share [Abstract] Computation of basic and diluted net loss per share [Abstract] -- None. No documentation exists for this element. -- Net income Net Income (Loss) Attributable to Parent Denominator for basic earnings per share - weighted average shares (in shares) Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted Income (loss) per common share - basic (in dollars per share) Earnings Per Share, Basic Income (loss) per common share - diluted (in dollars per share) Earnings Per Share, Diluted Summary of Antidilutive Securities [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding Stock Options Employee Stock Option [Member] Outstanding Warrants Warrant [Member] Restricted Stock Awards Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of business segments Number of Operating Segments Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents Patents [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Increase (decrease) in inventories Increase (Decrease) in Inventories Amortization of inventory fair value step-up Inventory Write-down Intangible assets, net of accumulated amortization Finite-Lived Intangible Assets, Period Increase (Decrease) Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Short term investments Short-term Investments Accounts receivable, net Accounts Receivable, Net, Current Inventory, net Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Property and equipment, net of accumulated depreciation Property, Plant and Equipment, Net Goodwill Goodwill Intangible assets, net of accumulated amortization Intangible Assets, Net (Excluding Goodwill) Deferred tax asset, net Deferred Income Tax Assets, Net Deferred financing costs and other assets Deferred Costs and Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Current portion of earn out liability Business Combination, Contingent Consideration, Liability, Current Other current liabilities Other Liabilities, Current Total current liabilities Earn out liability Business Combination, Contingent Consideration, Liability, Noncurrent Other liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding Preferred Stock, Value, Issued Common stock; $.001 par value; 150,000,000 shares authorized; 110,025,697 issued and 110,022,283 outstanding at June 30, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury stock at cost: 3,414 shares at June 30, 2016 and 2,105,945 shares at December 31, 2015 Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract] Supplemental disclosure of cash flow and non cash investing and financing activities [Abstract] -- None. No documentation exists for this element. -- Cash paid for interest Interest Paid Income taxes paid Income Taxes Paid Stock issuance of 441,009 shares in connection with acquisition Stock Issued During Period, Value, Acquisitions Shares issued in conjunction with acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Retirement of fixed assets Write-off of Fixed Assets Write-off of Fixed Assets Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively Stock Issued During Period, Value, Issued for Services Shares issued for services performed (in shares) Stock Issued During Period, Shares, Issued for Services Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts Receivable Receivables, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Sales of Goods [Policy Text Block] Acquisitions Business Combinations Policy [Policy Text Block] Patent Costs Legal Costs, Policy [Policy Text Block] Treasury Stock Stockholders' Equity, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Stockholders' equity: Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Customer relationships Customer Relationships [Member] Patents and know-how Non compete agreements Noncompete Agreements [Member] Licenses and permits Licensing Agreements [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Trade names and trademarks Trademarks and Trade Names [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long-term debt Loans Payable [Member] Line of credit Line of Credit [Member] Shareholder loan Shareholder Debt [Member] Shareholder Debt [Member] Business Combination, Consideration Transferred [Abstract] Business Combination, Consideration Transferred [Abstract] Working capital adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Common stock issued (441,009 shares valued at $9.07 per share) Common stock issued, price per share (in dollars per share) Business Acquisition, Share Price Total fair value of purchase price Business Combination, Consideration Transferred Net assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Debt-free working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital Other assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Subtotal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net Finite-Lived intangibles assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Indefinite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Subtotal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Total Assets Purchased Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Prepaid Expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Accounts Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Accounts Receivable Federal and state taxes receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Taxes Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Taxes Receivable Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Debt-free working capital Current portion of long term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Net working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital Other long term assets Commitments and Contingencies Disclosure [Abstract] Contractual Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Equity [Abstract] Stock Options Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock Options Outstanding and Exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Fair Value of Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Restricted Stock Awards Roll Forward Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Allocation of Share-based Compensation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Property, Plant and Equipment [Abstract] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Property, Plant and Equipment [Table Text Block] Inventory Schedule of Inventory, Current [Table Text Block] Revenue Business Acquisition, Pro Forma Revenue Income per share, fully diluted (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Estimated future amortization expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2016 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Net book value Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Assets Held under Capital Leases Assets Held under Capital Leases [Member] Leasehold Improvements Paid by Others Leasehold Improvements Paid by Others [Member] Leasehold Improvements Paid by Others [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Capital leases interest rate effective percentage, minimum Capital Leases Interest Rate Effective Percentage Minimum Minimum effective interest rate for the capital lease. Capital leases interest rate effective percentage, maximum Capital Leases Interest Rate Effective Percentage Maximum Maximum effective interest rate for the capital lease. Depreciation Depreciation Estimated annual lease, royalty, and employment agreement expenses [Abstract] Contractual Obligation, Fiscal Year Maturity [Abstract] 2017 Contractual Obligation, Due in Next Fiscal Year 2018 Contractual Obligation, Due in Second Year 2019 Contractual Obligation, Due in Third Year 2020 Contractual Obligation, Due in Fourth Year Thereafter Contractual Obligation, Due after Fifth Year Total Contractual commitments Contractual Obligation Estimated useful life (in years) Finite-Lived Intangible Asset, Useful Life Supplemental disclosure of cash flow and non-cash investing and financing activities Cash Flow, Supplemental Disclosures [Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Maximum borrowing capacity (up to) Line of Credit Facility, Maximum Borrowing Capacity Uncommitted incremental facility (up to) Line of Credit Facility, Uncommitted Incremental Facility Line of Credit Facility, Uncommitted Incremental Facility Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt issuance costs Debt Issuance Costs, Net Debt term Debt Instrument, Term Outstanding line of credit Long-term Line of Credit Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid - in Capital Additional Paid-in Capital [Member] Treasury Stock Treasury Stock [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, beginning of period Balance (in shares) Shares, Outstanding Share-based compensation expense Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Restricted stock shares cancelled/forfeited Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted stock shares cancelled/forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Shares issued for services performed Stock repurchase Treasury Stock, Value, Acquired, Cost Method Stock repurchase (in shares) Treasury Stock, Shares, Acquired Shares repurchased for tax withholding Adjustments Related to Tax Withholding for Share-based Compensation Shares repurchased for tax withholding (in shares) Shares Paid for Tax Withholding for Share Based Compensation Shares issued in conjunction with acquisition Net income Balance, end of period Balance (in shares) Leasehold improvements Leasehold Improvements [Member] Lab and clean room equipment Equipment [Member] Furniture and office equipment Furniture and Fixtures [Member] Construction in progress Construction in Progress [Member] Property and equipment, gross Property, Plant and Equipment, Gross Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Intangible assets activity summary Schedule of Intangible assets activity [Table Text Block] Tabular disclosure of intangible assets activity, which may be broken down by segment or major class. Estimated future amortization expense for intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Tradenames & trademarks Trade names and trademarks [Member] Rights acquired through registration of a business name to gain or protect exclusive use thereof and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. In process research & development In Process Research and Development [Member] Patents in process Patents in Process [Member] Patents in Process Licenses Customer & supplier relationships Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Surgical Biologics, LLC Surgical Biologics [Member] Represents Surgical Biologics, LLC ("Surgical Biologics"), a privately held company headquartered in Kennesaw, Georgia. which the Company acquired through an Agreement and Plan of Merger ("the Merger Agreement") with Membrane Products Holdings, LLC and Ramp Capital Investments, LLC on December 21, 2010. Weighted average amortization lives (in years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Gross carrying value Finite-Lived Intangible Assets, Gross Gross carrying value, indefinite lived Indefinite-Lived Intangible Assets (Excluding Goodwill) Total Intangible Assets, Gross (Excluding Goodwill) Less Accumulated amortization and impairment charges Intangible Assets, Accumulated Amortization And Impairment Charges Intangible Assets, Accumulated Amortization And Impairment Charges Net Acquisition price Payments to Acquire Intangible Assets Maximum time of approval (in days) Period of approval, maximum The maximum amount of time the entity has to obtain approval by the FDA to allow the sale of the product. Contingent royalty to be paid to licensor Contingent royalty to be paid to licensor Royalty payment percentage on all commercial sales revenue from the licensed products. Annual royalty payment, minimum Royalty Expense Finite-Lived Intangible Assets, Costs Finite-lived Intangible Assets Acquired Equity Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Intangible Assets and Royalty Agreement Intangible Assets Disclosure [Text Block] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule II - Valuation and Qualifying Accounts Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Authorized share amount for repurchase (up to) Stock Repurchase Program, Authorized Amount Shares repurchased, value Payments for Repurchase of Common Stock Brokerage commissions Treasury Stock, Brokerage Commissions Treasury Stock, Brokerage Commissions Remaining authorizations under the repurchase program Stock Repurchase Program, Remaining Authorized Repurchase Amount Shares reissued from the treasury (in shares) Stock Issued During Period, Shares, Treasury Stock Reissued Shares reissued from the treasury, value Stock Issued During Period, Value, Treasury Stock Reissued Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $0.50 - $0.76 Price Range 1 [Member] Price Range 1 [Member] $0.87 - $1.35 Price Range 2 [Member] Price Range 2 [Member] $1.40 - $2.45 Price Range 3 [Member] Price Range 3 [Member] $2.66 - $3.99 Price Range 4 [Member] Price Range 4 [Member] $4.19 - $6.38 Price Range 5 [Member] Price Range 5 [Member] $6.45 - $9.78 Price Range 6 [Member] Price Range 6 [Member] $9.90- $10.99 Price Range 7 [Member] Price Range 7 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of share-based compensation plans Number of share based compensation plans The number of share-based compensation the company maintains. Number of shares [Roll forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Unvested options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Vested options expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, end of period (in shares) Vested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Exercisable options, vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price [Roll forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, weighted average exercise price, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Unvested options forfeited, weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Vested options expired, weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, weighted average exercise price, end of period (in dollars per share) Vested at end of period, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and expected to vest, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Stock options, additional disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Outstanding Options, weighted average remaining contractual term (in years) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Vested at end of period, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and expected to vest, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested at end of period, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Vested or expected to vest, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercised options, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Exercise Price Range, lower range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise Price Range, upper range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Number of outstanding options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Outstanding Options, weighted average remaining contractual term (in years) Outstanding Options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Number of exercisable options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercisable Options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Total unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Fair value options valuation assumptions [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Expected volatility Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Risk-free interest rate Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Income Statement [Abstract] Net sales Sales Revenue, Goods, Net Cost of sales Cost of Goods Sold Gross margin Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development expenses Research and Development Expense Selling, general and administrative expenses Selling, General and Administrative Expense Operating income Operating Income (Loss) Other income (expense), net Nonoperating Income (Expense) [Abstract] Interest income (expense), net Other Nonoperating Income (Expense) Income before income tax provision Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Net income Net income per common share - basic (in dollars per share) Net income per common share - diluted (in dollars per share) Weighted average shares outstanding - basic (in shares) Weighted average shares outstanding - diluted (in shares) Cash and Cash Equivalents [Abstract] Investment [Table] Investment [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Certificates of Deposit Certificates of Deposit [Member] Investment [Line Items] Investment [Line Items] Schedule of Acquisition of Stability Inc. Schedule of Business Acquisitions, by Acquisition [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Cost of sales Cost of Sales [Member] Research and development Research and Development Expense [Member] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, Beginning Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, Ending Balance (in shares) Weighted- Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, Beginning Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, Ending Balance (in dollars per share) Total unrecognized stock-based compensation related to time-based, nonvested restricted stock Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Expenses expected to be recognized over a weighted-average period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Share-based Compensation [Abstract] Share-based Compensation [Abstract] Share-based compensation expense Allocated Share-based Compensation Expense Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Estimated Annual Lease, Royalty and Employment Agreement Expenses Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Inventory, gross Inventory, Gross Reserve for obsolescence Inventory Valuation Reserves Inventory, net Acquisition of Stability Inc. Business Combination Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Share-based compensation Share-based Compensation Increase (decrease) in cash, net of effects of acquisition, resulting from changes in: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Deferred Compensation Accrued expenses Increase (Decrease) in Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of equipment Payments to Acquire Machinery and Equipment Purchase of Stability Inc., net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Fixed maturity securities redemption Proceeds from Sale and Maturity of Held-to-maturity Securities Patent application costs Payments for Application Costs, Patent Payments for Application Costs, Patent Net cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Stock repurchase under repurchase plan Proceeds from (Repurchase of) Equity Stock repurchase for tax withholdings on vesting of restricted stock Payments Related to Tax Withholding for Share-based Compensation Deferred financing costs Payments of Debt Issuance Costs Payments under capital lease obligations Payments to Acquire Equipment on Lease Net cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Income taxes Income Tax Disclosure [Text Block] Short Term Investments Cash, Cash Equivalents, and Short-term Investments [Text Block] Loss Contingencies Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Standby Letters of Credit Standby Letters of Credit [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Revenue, Net Sales Revenue, Net [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Product Concentration Risk Product Concentration Risk [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending Litigation Pending Litigation [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Liventa Action Liventa Action [Member] Liventa Action [Member] Bone Bank Action Bone Bank Action [Member] Bone Bank Action [Member] Liventa Action, 701 Patent Liventa Action, 701 Patent [Member] Liventa Action, 701 Patent [Member] Liventa Action, 437 Patent Liventa Action, 437 Patent [Member] Liventa Action, 437 Patent [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Lease expiration period (in years) Lessee Leasing Arrangements, Operating Leases, Term of Contract Rent expense Operating Leases, Rent Expense Standby letters of credit Letters of Credit Outstanding, Amount Percentage of revenue Concentration Risk, Percentage Number of patent challenged grounds Loss Contingency, Pending Claims, Number Number of pending disputed claim terms Loss Contingency, Pending Disputed Claim Terms, Number Loss Contingency, Pending Disputed Claim Terms, Number Opinion allowing a review of patent Loss Contingency, Pending Claims, Allowed for Review, Number Loss Contingency Pending Claims Number Allowed for Review EX-101.PRE 14 mdxg-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 15 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2016
Jul. 15, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name MIMEDX GROUP, INC.  
Entity Central Index Key 0001376339  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   110,042,283
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2016  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 23,803 $ 28,486
Short term investments 0 3,000
Accounts receivable, net 54,861 53,755
Inventory, net 17,207 7,460
Prepaid expenses and other current assets 5,970 3,609
Total current assets 101,841 96,310
Property and equipment, net of accumulated depreciation 13,049 9,475
Goodwill 26,951 4,040
Intangible assets, net of accumulated amortization 27,693 10,763
Deferred tax asset, net 7,077 14,838
Deferred financing costs and other assets 444 487
Total assets 177,055 135,913
Current liabilities:    
Accounts payable 9,678 6,633
Accrued compensation 10,245 15,034
Accrued expenses 6,988 4,644
Current portion of earn out liability 9,642 0
Other current liabilities 1,985 466
Total current liabilities 38,538 26,777
Earn out liability 15,978 0
Other liabilities 934 1,148
Total liabilities 55,450 27,925
Commitments and contingencies
Stockholders' equity:    
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding 0 0
Common stock; $.001 par value; 150,000,000 shares authorized; 110,025,697 issued and 110,022,283 outstanding at June 30, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 110 109
Additional paid-in capital 156,457 163,133
Treasury stock at cost: 3,414 shares at June 30, 2016 and 2,105,945 shares at December 31, 2015 (4) (17,124)
Accumulated deficit (34,958) (38,130)
Total stockholders' equity 121,605 107,988
Total liabilities and stockholders' equity $ 177,055 $ 135,913
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2016
Dec. 31, 2015
Stockholders' equity:    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 110,025,697 109,467,416
Common stock, shares outstanding (in shares) 110,022,283 107,361,471
Treasury stock, shares (in shares) 3,414 2,105,945
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Income Statement [Abstract]        
Net sales $ 57,342 $ 45,679 $ 110,710 $ 86,446
Cost of sales 7,394 5,089 15,341 10,237
Gross margin 49,948 40,590 95,369 76,209
Operating expenses:        
Research and development expenses 3,168 2,054 5,664 3,885
Selling, general and administrative expenses 42,772 32,651 83,420 61,960
Amortization of intangible assets 447 233 1,257 465
Operating income 3,561 5,652 5,028 9,899
Other income (expense), net        
Interest income (expense), net (111) 1 (167) (13)
Income before income tax provision 3,450 5,653 4,861 9,886
Income tax provision (1,475) (223) (1,689) (369)
Net income $ 1,975 $ 5,430 $ 3,172 $ 9,517
Net income per common share - basic (in dollars per share) $ 0.02 $ 0.05 $ 0.03 $ 0.09
Net income per common share - diluted (in dollars per share) $ 0.02 $ 0.05 $ 0.03 $ 0.08
Weighted average shares outstanding - basic (in shares) 106,191,932 106,211,120 105,873,727 106,013,752
Weighted average shares outstanding - diluted (in shares) 112,148,415 114,186,329 112,095,051 113,892,087
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2016 - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid - in Capital
Treasury Stock
Accumulated Deficit
Balance, beginning of period at Dec. 31, 2015 $ 107,988 $ 109 $ 163,133 $ (17,124) $ (38,130)
Balance (in shares) at Dec. 31, 2015   109,467,416   2,105,945  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation expense 9,124   9,124    
Exercise of stock options $ 2,016   (2,745) $ 4,761  
Exercise of stock options (in shares) 804,041 223,928   (580,113)  
Issuance of restricted stock $ 0 $ 1 (13,422) $ 13,421  
Issuance of restricted stock (in shares)   334,353   (1,660,079)  
Restricted stock shares cancelled/forfeited 0   825 $ (825)  
Restricted stock shares cancelled/forfeited (in shares)       102,230  
Shares issued for services performed $ 173   4 $ 169  
Shares issued for services performed (in shares) 20,406     (20,406)  
Stock repurchase $ (3,530)     $ (3,530)  
Stock repurchase (in shares) 415,252     415,252  
Shares repurchased for tax withholding $ (684)     $ (684)  
Shares repurchased for tax withholding (in shares)       81,594  
Shares issued in conjunction with acquisition $ 3,346   (462) $ 3,808  
Shares issued in conjunction with acquisition (in shares) 441,009     (441,009)  
Net income $ 3,172       3,172
Balance, end of period at Jun. 30, 2016 $ 121,605 $ 110 $ 156,457 $ (4) $ (34,958)
Balance (in shares) at Jun. 30, 2016   110,025,697   3,414  
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash flows from operating activities:    
Net income $ 3,172 $ 9,517
Adjustments to reconcile net income to net cash from operating activities:    
Depreciation 1,555 776
Amortization of intangible assets 1,257 465
Amortization of inventory fair value step-up 1,224 0
Amortization of deferred financing costs 91 0
Share-based compensation 9,124 8,186
Increase (decrease) in cash, net of effects of acquisition, resulting from changes in:    
Accounts receivable 894 (12,776)
Inventory (2,245) 1,274
Prepaid expenses and other current assets (1,781) (1,106)
Other assets (264) (26)
Accounts payable (5,597) 2,060
Accrued compensation (4,789) (1,862)
Accrued expenses 2,344 1,221
Other liabilities 1,318 (586)
Net cash flows from operating activities 6,303 7,143
Cash flows from investing activities:    
Purchases of equipment (3,755) (2,513)
Purchase of Stability Inc., net of cash acquired (7,631) 0
Fixed maturity securities redemption 3,000 1,750
Patent application costs (327) (402)
Net cash flows from investing activities (8,713) (1,165)
Cash flows from financing activities:    
Proceeds from exercise of stock options 2,016 2,741
Stock repurchase under repurchase plan (3,530) (16,641)
Stock repurchase for tax withholdings on vesting of restricted stock (684) 0
Deferred financing costs (61) 0
Payments under capital lease obligations (14) (59)
Net cash flows from financing activities (2,273) (13,959)
Net change in cash (4,683) (7,981)
Cash and cash equivalents, beginning of period 28,486 46,582
Cash and cash equivalents, end of period $ 23,803 $ 38,601
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation
 6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the six months ended June 30, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology, CollaFix™, which the Company has yet to commercialize. Through the recent acquisition of Stability Inc., our newest proprietary platforms include Physio®, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn™, a skin product for burns.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Significant Accounting Policies
Significant Accounting Policies
Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2015, for a description of all significant accounting policies. 
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of June 30, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately $800,000, which is comprised of approximately $2.0 million as of the date of the acquisition less amortization of approximately $1.2 million during the six months ended June 30, 2016. Please see Note 4 contained herein.


Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $327,000 of patent costs during the first six months of 2016. The Company capitalized approximately $402,000 of patent costs during the first six months of 2015.
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and
not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with
Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when
companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting
periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company
is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, 'Balance Sheet Classification of Deferred Taxes'. ASU 2015-17
simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the
balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,
and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption
is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify
reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.

In February 2016, the FASB issued ASU No. 2016-02, 'Leases (Topic 842)'. The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is
intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.

All other ASUs issued and not yet effective for the six months ended June 30, 2016, and through the date of this report,
were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial
position or results of operations.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Liquidity and Management's Plans
 6 Months Ended
Jun. 30, 2016
Liquidity and management's plans [Abstract]  
Liquidity and Management's Plans
Liquidity and Management’s Plans
As of June 30, 2016, the Company had approximately $23,803,000 of cash and cash equivalents.  The Company reported total current assets of approximately $101,841,000 and current liabilities of approximately $38,538,000 as of June 30, 2016.  The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc.
 6 Months Ended
Jun. 30, 2016
Business Combinations [Abstract]  
Acquisition of Stability Inc.
Acquisition of Stability Inc.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human
tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare
industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for
$6,000,000 cash, $3,346,000 in stock, represented by 441,009 shares of our common stock, and assumed debt of $1,771,000. Additional one time costs incurred in connection with the transaction totaled $851,000 and are included withing selling, general and administrative expenses on the condensed consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of June 30, 2016, the contingent consideration was valued at $25,620,000 and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability.

The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the
contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument,
other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number
of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or
predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs
associated with the combination. The actual purchase price has been preliminarily allocated as of June 30, 2016 (in
thousands) and is subject to change:

Cash paid at closing
 
$
6,000

Working capital adjustment
 
(480
)
Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn-out
 
25,620

Total fair value of purchase price
 
$
36,257

 
 
 
Net assets acquired:
 

Debt-free working capital
 
$
2,179

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(8,268
)
Subtotal
 
(4,515
)
Intangible assets:
 
 
Customer relationships
 
6,090

Patents and know-how
 
9,170

Trade names and trademarks
 
830

Non compete agreements
 
1,080

Licenses and permits
 
690

Subtotal
 
17,860

Goodwill
 
22,912

Total Assets Purchased
 
$
36,257

 
 
 
Working capital and other assets were composed of the following (in thousands):
 
 
Working capital
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
8,725

Accounts payable and accrued expenses
 
(8,815
)
Debt-free working capital
 
$
2,179

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of Credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
408

 
 

Other assets:
 
 
Other long term assets
 
$
199



The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - Business Combinations.
The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is
recorded at fair value on the acquisition date and will be remeasured quarterly until purchase accounting is completed based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization.The intangible assets were assigned the following lives for amortization purposes:

 
 
Estimated useful life (in years)
Intangible asset:
 
 
Customer relationships
 
12
Patents and know-how
 
20
Trade name and Trademarks
 
Indefinite
Non compete agreements
 
4
Licenses and permits
 
2


Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value.
Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in
the transaction and is preliminary as of June 30, 2016 and is subject to change. Goodwill is tested for impairment on an annual basis as definedby FASB Topic 350 - "Intangibles - Goodwill and Other".

The following unaudited pro forma summary financial information presents the consolidated results of operations as if the
acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport
to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative
of the results that may occur in the future.

Unaudited pro forma information for the three and six months ended June 30, 2016 and 2015 (in thousands) is as follows:

 
 
Three months ended June 30,
 
Six months ended June 30,
 
 
2016
2015
 
2016
2015
Revenue
 
$
57,342

$
50,492

 
$
111,258

$
96,413

 
 
 
 
 
 
 
Net income
 
$
2,057

$
4,919

 
$
3,668

$
7,975

 
 
 
 
 
 
 
Income per share, fully diluted
 
$
0.02

$
0.04

 
$
0.03

$
0.07



The 2016 supplemental pro forma earnings were adjusted to exclude $851,000 of acquisition-related legal, audit and other
costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include $787,000 of amortization costs related to
recorded intangible assets with defined useful lives, and $1,224,000 of inventory step-up charges as a result of the acquisition
for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include 441,009 shares issued as part of the purchase price and assumed to be issued on January 1, 2015.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Short Term Investments
 6 Months Ended
Jun. 30, 2016
Cash and Cash Equivalents [Abstract]  
Short Term Investments
Short Term Investments
Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories
 6 Months Ended
Jun. 30, 2016
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following items as of June 30, 2016, and December 31, 2015 (in thousands):
 
June 30, 2016
 
December 31, 2015
Raw materials
$
1,154

 
$
602

Work in process
5,888

 
3,850

Finished goods
11,945

 
3,405

 Inventory, gross
18,987

 
7,857

Reserve for obsolescence
(1,780
)
 
(397
)
 Inventory, net
$
17,207

 
$
7,460
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment
 6 Months Ended
Jun. 30, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and Equipment 
Property and equipment consist of the following as of June 30, 2016, and December 31, 2015 (in thousands):
 
June 30,
2016
 
December 31,
2015
Leasehold improvements
$
3,245

 
$
2,684

Lab and clean room equipment
8,196

 
4,564

Furniture and office equipment
6,167

 
4,577

Construction in progress
2,169

 
2,629

   Property and equipment, gross
19,777

 
14,454

Less accumulated depreciation
(6,728
)
 
(4,979
)
   Property and equipment, net
$
13,049

 
$
9,475


Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $72,000 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately 3% to 12% with maturity dates from September 2016 to January 2018.
Also included is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
Depreciation expense for the six months ended June 30, 2016 and 2015, was approximately $1,555,000 and $776,000, respectively, and approximately $821,000 and $422,000 for the three months ended June 30, 2016 and 2015, respectively.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement
 6 Months Ended
Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Royalty Agreement
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
June 30, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (d)
7 years
 
$
1,699

 
$
1,009

Patents & Know How (b) (d)
19 years
 
17,176

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
9,851

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
1,838

 
1,008

Non-compete agreements (d)
4 years
 
1,080

 
—

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
2,146

 
1,823

Total
 
 
33,815

 
15,627

Less Accumulated amortization and impairment charges
 
 
(6,122
)
 
(4,864
)
Net
 
 
$
27,693

 
$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the six months ended June 30, 2016, approximately $4,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents & Know - How of $9,170,000, Customer Relationships of $6,090,000, Non - compete agreements of$1,080,000, Tradenames & Trademarks of $830,000 and Licenses of $690,000.
Amortization expense for the six months ended June 30, 2016 and 2015, was approximately $1,257,000 and $465,000, respectively, and $447,000 and $233,000 for three months ended June 30, 2016 and 2015, respectively.
Expected future amortization of intangible assets as of June 30, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
1,259

2017
2,427

2018
2,072

2019
2,072

2020
1,802

Thereafter
16,223

 
$
25,855

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after June 30, 2016.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Credit Facility
 6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]  
Credit Facility
Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain
lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving
credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to
$50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be
exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and
conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%.
Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs
are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary
representations, warranties, covenants, and events of default. As of June 30, 2016, there were no outstanding revolving loans
under the credit facility.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share
Net Income (Loss) Per Share
Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Net income
$
1,975

 
$
5,430

 
$
3,172

 
$
9,517

Denominator for basic earnings per share - weighted average shares
106,191,932

 
106,211,120

 
105,873,727

 
106,013,752

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
5,956,483

 
7,975,209

 
6,221,324

 
7,878,335

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,148,415

 
114,186,329

 
112,095,051

 
113,892,087

Income per common share - basic
$
0.02

 
$
0.05

 
$
0.03

 
$
0.09

Income per common share - diluted
$
0.02

 
$
0.05


$
0.03


$
0.08

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Outstanding Stock Options
5,644,128

 
7,411,271

 
5,805,870

 
7,393,698

Outstanding Warrants
—

 
37,909

 
—

 
37,708

Restricted Stock Awards
312,355

 
526,029

 
415,454

 
446,929

 
5,956,483

 
7,975,209

 
6,221,324

 
7,878,335
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity
 6 Months Ended
Jun. 30, 2016
Equity [Abstract]  
Equity
Equity
Stock Incentive Plans 
The Company has four share-based compensation plans: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016, the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2016 Plan to make future grants.
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(804,041
)
 
$
2.51

 
 
 
 
Unvested options forfeited
(79,810
)
 
$
6.44

 
 
 
 
Vested options expired
(29,191
)
 
$
6.44

 
 
 
 

Outstanding at June 30, 2016
13,106,587

 
$
3.67

 
6.0
 
$
56,844,050

Vested at June 30, 2016
11,710,880

 
$
3.27

 
5.8
 
$
55,362,178

Vested or expected to vest at June 30, 2016 (a)
13,047,941

 
$
3.66

 
6.0
 
$
56,809,041

(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the six months ended June 30, 2016, was approximately $4,937,922. 
Following is a summary of stock options outstanding and exercisable at June 30, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
2.9
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,420,470

 
5.2
 
1.19

 
4,420,470

 
1.19

$1.40 - $2.45
1,458,424

 
4.4
 
1.92

 
1,458,424

 
1.92

$2.66 - $3.99
889,430

 
6.3
 
3.06

 
889,430

 
3.06

$4.19 - $6.38
3,310,253

 
6.9
 
5.36

 
2,898,133

 
5.28

$6.45 - $9.78
2,479,415

 
7.6
 
7.29

 
1,586,502

 
7.23

$9.90- $10.99
107,166

 
8.4
 
10.43

 
36,492

 
10.44

 
13,106,587

 
6.0
 
$
3.67

 
11,730,880

 
$
3.27

 
Total unrecognized compensation expense related to granted stock options at June 30, 2016, was approximately $3,283,152 and will be charged to expense ratably through May 2018. 
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
 
Six Months Ended June 30,
 
2016
 
2015
Expected volatility
n/a
 
54.4 - 58.1 %

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 
—

Risk-free interest rate
n/a
 
1.51% - 1.68%


There were no options granted during the six months ended June 30, 2016.
Restricted Stock Awards                                                    
Activity with respect to restricted stock awards is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
2,014,838

 
8.04
Vested
(825,595
)
 
8.63
Forfeited
(102,230
)
 
8.85

Unvested at June 30, 2016
3,700,280

 
$8.66

As of June 30, 2016, there was approximately $24,939,716 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.1 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at June 30, 2016.
For the three and six months ended June 30, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Cost of sales
$
95

 
$
90

 
$
190

 
$
184

Research and development
155

 
203

 
360

 
389

Selling, general and administrative
4,253

 
3,962

 
8,574

 
7,613

 
$
4,503

 
$
4,255

 
$
9,124

 
$
8,186


Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the six months ended June 30, 2016, the Company purchased 415,252 shares of its common stock for a purchase price of approximately $3,518,000 before brokerage commissions of approximately $12,000. As of June 30, 2016, the Company had approximately $10,756,000 of availability remaining under the repurchase program.
Additionally, for the six months ended June 30, 2016, the Company reissued 2,599,377 shares from the Treasury for restricted stock grants and stock option exercises, net of forfeitures, and as partial consideration to the shareholders of Stability, with an aggregate carrying value of approximately $21,334,000.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income taxes
 6 Months Ended
Jun. 30, 2016
Income Tax Disclosure [Abstract]  
Income taxes
Income taxes 

The effective tax rates for continuing operations of 34.7% and 3.7% for the six months ended June 30, 2016 and June 30, 2015, respectively, were determined using an estimated annual effective tax rate and include, in 2016, the impact of a discrete item of approximately $350,000. The effective tax rate for the 2016 period increased approximately 31% when compared to the same period of 2015, primarily due to the $15.4 million valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the six months ended June 30, 2015, did not include the expense of the current period U.S. taxable income. As of the end of June 2016, the projected annual effective tax rate for 2016 is 42.2%.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental disclosure of cash flow and non-cash investing and financing activities
 6 Months Ended
Jun. 30, 2016
Supplemental Cash Flow Elements [Abstract]  
Supplemental disclosure of cash flow and non-cash investing and financing activities
Supplemental disclosure of cash flow and non-cash investing and financing activities:
    
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Six Months Ended June 30,
 
2016
 
2015
Cash paid for interest
$
76

 
$
29

Income taxes paid
631

 
874

Stock issuance of 441,009 shares in connection with acquisition
3,346

 
—

Retirement of fixed assets
—

 
308

Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively
173

 
108
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Contractual Commitments and Contingencies
 6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Contractual Commitments and Contingencies
Contractual Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next eight years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended June 30
2017
$
3,310

2018
3,128

2019
2,052

2020
1,366

Thereafter
644

 
$
10,500



Rent expense for the six months ended June 30, 2016 and 2015, was approximately $859,000 and $593,000, respectively, and was approximately $436,000 and $310,000 for the three months ended June 30, 2016 and 2015, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit
As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $118,000. These obligations are reduced at various times over the life of the lease.
FDA Untitled Letter and Draft Guidance
On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has indicated that it will hold a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The hearing was originally scheduled for April 13, 2016, but was rescheduled to September 2016 in order to allow stakeholders additional time to provide comments due to the considerable interest in the hearing. The Company has requested, and has been granted, an opportunity to speak at the rescheduled hearing. The FDA has also scheduled a related scientific workshop to be held prior to the hearing to identify and discuss the scientific considerations and challenges to help inform the development of HCT/Ps.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues for the fiscal year ended December 31, 2015.

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Norther District of Georgia against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached an amicable settlement of the False Advertising Claims for an undisclosed sum. The patent infringement claims are still pending as described below.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below.

In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the ’437 and ’687 Patents, seeking a partial stay of the litigation as to the ’437, ’687, and ’494 Patents (i.e., the ’437 Patent family). MiMedx opposed the Motion to Stay with respect to the ’494 Patent and once again successfully defeated Defendants’ motion to stay.



On December 22, 2015, a Markman Hearing was held before a Special Master. Over thirty disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for one term, the Special Master’s Report essentially adopted MiMedx’s proposed constructions. On March 9, 2016, the Court adopted the Special Master’s Report. Since then the Court has entered a scheduling order in this action. Fact discovery has closed and the parties are currently engaging in expert discovery, which is expected to close in early September 2016. We expect the case to go to trial in late 2016.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, Defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. The Markman hearing in this case was held on October 2, 2015. Except for one term, the Court adopted MiMedx’s proposed construction of the disputed terms. Fact discovery has closed and the parties are currently engaging in expert discovery, which is expected to close in August 2016. We expect the case to go to trial in the fall of 2016.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On November 24, 2015, the court ruled on NuTech’s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement, as well as violations of the Lanham Act which are still pending.

On January 8, 2016, the parties submitted their Initial Disclosures, and MiMedx submitted its preliminary infringement contentions. On March 14, 2016, Defendants submitted their preliminary invalidity contentions. On April 15, 2016, the parties exchanged proposed terms for construction and over the next several months the parties will engage in claim construction briefing and related proceedings. Discovery is ongoing.

The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "494" patent). Vivex answered MiMedx’s Complaint and filed Counterclaims of noninfringement and invalidity.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "687" patent) and the 494 patent; while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all seven challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The parties decided to forego oral arguments. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment not configuration, were invalid for obviousness. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. A decision is expected no later than August of 2016.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Subsequent Events
 6 Months Ended
Jun. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
None
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Schedule II - Valuation and Qualifying Accounts
 6 Months Ended
Jun. 30, 2016
Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
 Three and Six Months Ended June 30, 2016 and 2015 (in thousands)
 
 
 
 
 
 
 
 
Balance at
Beginning of Period
Additions charged to Expense or Revenue
Deductions
and write-offs
Balance at
End of Period
 
 
 
 
 
 
For the three months ended June 30, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
3,872

$
233

$
(19
)
$
4,086

 Allowance for product returns
 
1,708

2,106

(1,623
)
2,191

 Allowance for obsolescence
 
604

1,335

(159
)
1,780

 
 
 
 
 
 
For the three months ended June 30, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
2,010

$
500

$
(6
)
$
2,504

 Allowance for product returns
 
944

734

(648
)
1,030

 Allowance for obsolescence
 
552

90

(89
)
553

 
 
 
 
 
 
For the six months ended June 30, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
3,270

$
835

$
(19
)
$
4,086

 Allowance for product returns
 
1,262

3,467

(2,538
)
2,191

 Allowance for obsolescence
 
397

1,570

(187
)
1,780


 
 
 
 
 
For the six months ended June 30, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
1,750

$
760

$
(6
)
$
2,504

 Allowance for product returns
 
841

1,443

(1,254
)
1,030

 Allowance for obsolescence
 
527

221

(195
)
553
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the six months ended June 30, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
Segment Reporting
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology, CollaFix™, which the Company has yet to commercialize. Through the recent acquisition of Stability Inc., our newest proprietary platforms include Physio®, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn™, a skin product for burns.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of June 30, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately $800,000, which is comprised of approximately $2.0 million as of the date of the acquisition less amortization of approximately $1.2 million during the six months ended June 30, 2016. Please see Note 4 contained herein.
Revenue Recognition
Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets.
Treasury Stock
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and
not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with
Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when
companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting
periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company
is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, 'Balance Sheet Classification of Deferred Taxes'. ASU 2015-17
simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the
balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,
and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption
is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify
reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.

In February 2016, the FASB issued ASU No. 2016-02, 'Leases (Topic 842)'. The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is
intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.

All other ASUs issued and not yet effective for the six months ended June 30, 2016, and through the date of this report,
were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial
position or results of operations.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. (Tables)
 6 Months Ended
Jun. 30, 2016
Business Combinations [Abstract]  
Schedule of Acquisition of Stability Inc.
The actual purchase price has been preliminarily allocated as of June 30, 2016 (in
thousands) and is subject to change:

Cash paid at closing
 
$
6,000

Working capital adjustment
 
(480
)
Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn-out
 
25,620

Total fair value of purchase price
 
$
36,257

 
 
 
Net assets acquired:
 

Debt-free working capital
 
$
2,179

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(8,268
)
Subtotal
 
(4,515
)
Intangible assets:
 
 
Customer relationships
 
6,090

Patents and know-how
 
9,170

Trade names and trademarks
 
830

Non compete agreements
 
1,080

Licenses and permits
 
690

Subtotal
 
17,860

Goodwill
 
22,912

Total Assets Purchased
 
$
36,257

 
 
 
Working capital and other assets were composed of the following (in thousands):
 
 
Working capital
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
8,725

Accounts payable and accrued expenses
 
(8,815
)
Debt-free working capital
 
$
2,179

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of Credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
408

 
 

Other assets:
 
 
Other long term assets
 
$
199
Finite-Lived and Indefinite-Lived Intangible Assets Acquired
The intangible assets were assigned the following lives for amortization purposes:

 
 
Estimated useful life (in years)
Intangible asset:
 
 
Customer relationships
 
12
Patents and know-how
 
20
Trade name and Trademarks
 
Indefinite
Non compete agreements
 
4
Licenses and permits
 
2
Business Acquisition, Pro Forma Information
Unaudited pro forma information for the three and six months ended June 30, 2016 and 2015 (in thousands) is as follows:

 
 
Three months ended June 30,
 
Six months ended June 30,
 
 
2016
2015
 
2016
2015
Revenue
 
$
57,342

$
50,492

 
$
111,258

$
96,413

 
 
 
 
 
 
 
Net income
 
$
2,057

$
4,919

 
$
3,668

$
7,975

 
 
 
 
 
 
 
Income per share, fully diluted
 
$
0.02

$
0.04

 
$
0.03

$
0.07
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories (Tables)
 6 Months Ended
Jun. 30, 2016
Inventory Disclosure [Abstract]  
Inventory
Inventories consisted of the following items as of June 30, 2016, and December 31, 2015 (in thousands):
 
June 30, 2016
 
December 31, 2015
Raw materials
$
1,154

 
$
602

Work in process
5,888

 
3,850

Finished goods
11,945

 
3,405

 Inventory, gross
18,987

 
7,857

Reserve for obsolescence
(1,780
)
 
(397
)
 Inventory, net
$
17,207

 
$
7,460
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Tables)
 6 Months Ended
Jun. 30, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment consist of the following as of June 30, 2016, and December 31, 2015 (in thousands):
 
June 30,
2016
 
December 31,
2015
Leasehold improvements
$
3,245

 
$
2,684

Lab and clean room equipment
8,196

 
4,564

Furniture and office equipment
6,167

 
4,577

Construction in progress
2,169

 
2,629

   Property and equipment, gross
19,777

 
14,454

Less accumulated depreciation
(6,728
)
 
(4,979
)
   Property and equipment, net
$
13,049

 
$
9,475
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement (Tables)
 6 Months Ended
Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets activity summary
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
June 30, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (d)
7 years
 
$
1,699

 
$
1,009

Patents & Know How (b) (d)
19 years
 
17,176

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
9,851

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
1,838

 
1,008

Non-compete agreements (d)
4 years
 
1,080

 
—

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
2,146

 
1,823

Total
 
 
33,815

 
15,627

Less Accumulated amortization and impairment charges
 
 
(6,122
)
 
(4,864
)
Net
 
 
$
27,693

 
$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the six months ended June 30, 2016, approximately $4,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents & Know - How of $9,170,000, Customer Relationships of $6,090,000, Non - compete agreements of$1,080,000, Tradenames & Trademarks of $830,000 and Licenses of $690,000.
Estimated future amortization expense for intangible assets
Expected future amortization of intangible assets as of June 30, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
1,259

2017
2,427

2018
2,072

2019
2,072

2020
1,802

Thereafter
16,223

 
$
25,855

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after June 30, 2016.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share (Tables)
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Loss per Share
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Net income
$
1,975

 
$
5,430

 
$
3,172

 
$
9,517

Denominator for basic earnings per share - weighted average shares
106,191,932

 
106,211,120

 
105,873,727

 
106,013,752

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
5,956,483

 
7,975,209

 
6,221,324

 
7,878,335

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,148,415

 
114,186,329

 
112,095,051

 
113,892,087

Income per common share - basic
$
0.02

 
$
0.05

 
$
0.03

 
$
0.09

Income per common share - diluted
$
0.02

 
$
0.05


$
0.03


$
0.08

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Outstanding Stock Options
5,644,128

 
7,411,271

 
5,805,870

 
7,393,698

Outstanding Warrants
—

 
37,909

 
—

 
37,708

Restricted Stock Awards
312,355

 
526,029

 
415,454

 
446,929

 
5,956,483

 
7,975,209

 
6,221,324

 
7,878,335
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity (Tables)
 6 Months Ended
Jun. 30, 2016
Equity [Abstract]  
Stock Options Activity
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(804,041
)
 
$
2.51

 
 
 
 
Unvested options forfeited
(79,810
)
 
$
6.44

 
 
 
 
Vested options expired
(29,191
)
 
$
6.44

 
 
 
 

Outstanding at June 30, 2016
13,106,587

 
$
3.67

 
6.0
 
$
56,844,050

Vested at June 30, 2016
11,710,880

 
$
3.27

 
5.8
 
$
55,362,178

Vested or expected to vest at June 30, 2016 (a)
13,047,941

 
$
3.66

 
6.0
 
$
56,809,041

(a)
Includes forfeiture adjusted unvested shares.
Stock Options Outstanding and Exercisable
Following is a summary of stock options outstanding and exercisable at June 30, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
2.9
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,420,470

 
5.2
 
1.19

 
4,420,470

 
1.19

$1.40 - $2.45
1,458,424

 
4.4
 
1.92

 
1,458,424

 
1.92

$2.66 - $3.99
889,430

 
6.3
 
3.06

 
889,430

 
3.06

$4.19 - $6.38
3,310,253

 
6.9
 
5.36

 
2,898,133

 
5.28

$6.45 - $9.78
2,479,415

 
7.6
 
7.29

 
1,586,502

 
7.23

$9.90- $10.99
107,166

 
8.4
 
10.43

 
36,492

 
10.44

 
13,106,587

 
6.0
 
$
3.67

 
11,730,880

 
$
3.27
Fair Value of Options, Valuation Assumptions
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
 
Six Months Ended June 30,
 
2016
 
2015
Expected volatility
n/a
 
54.4 - 58.1 %

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 
—

Risk-free interest rate
n/a
 
1.51% - 1.68%
Restricted Stock Awards Roll Forward
Activity with respect to restricted stock awards is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
2,014,838

 
8.04
Vested
(825,595
)
 
8.63
Forfeited
(102,230
)
 
8.85

Unvested at June 30, 2016
3,700,280

 
$8.66
Allocation of Share-based Compensation
For the three and six months ended June 30, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Cost of sales
$
95

 
$
90

 
$
190

 
$
184

Research and development
155

 
203

 
360

 
389

Selling, general and administrative
4,253

 
3,962

 
8,574

 
7,613

 
$
4,503

 
$
4,255

 
$
9,124

 
$
8,186
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables)
 6 Months Ended
Jun. 30, 2016
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Six Months Ended June 30,
 
2016
 
2015
Cash paid for interest
$
76

 
$
29

Income taxes paid
631

 
874

Stock issuance of 441,009 shares in connection with acquisition
3,346

 
—

Retirement of fixed assets
—

 
308

Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively
173

 
108
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Contractual Commitments and Contingencies (Tables)
 6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Estimated Annual Lease, Royalty and Employment Agreement Expenses
The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended June 30
2017
$
3,310

2018
3,128

2019
2,052

2020
1,366

Thereafter
644

 
$
10,500
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation (Details)
 6 Months Ended
Jun. 30, 2016
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of business segments 1
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jan. 13, 2016
Jun. 30, 2016
Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]      
Increase (decrease) in inventories   $ 2,245 $ (1,274)
Amortization of inventory fair value step-up   1,224 0
Patents      
Finite-Lived Intangible Assets [Line Items]      
Intangible assets, net of accumulated amortization   327 $ 402
Fair Value Adjustment to Inventory      
Finite-Lived Intangible Assets [Line Items]      
Increase (decrease) in inventories $ 2,000 $ 800  
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Liquidity and Management's Plans (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Jun. 30, 2015
Dec. 31, 2014
Liquidity and management's plans [Abstract]        
Cash and cash equivalents $ 23,803 $ 28,486 $ 38,601 $ 46,582
Total current assets 101,841 96,310    
Total current liabilities $ 38,538 $ 26,777    
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 13, 2016
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Business Acquisition [Line Items]          
Amortization of intangible assets   $ 447 $ 233 $ 1,257 $ 465
Net income   2,057 $ 4,919 3,668 7,975
Fair Value Adjustment to Inventory          
Business Acquisition [Line Items]          
Net income         1,224
Pro Forma          
Business Acquisition [Line Items]          
Amortization of intangible assets         $ 787
Stability Biologics, LLC          
Business Acquisition [Line Items]          
Cash paid at closing $ 6,000        
Common stock issued $ 3,346        
Common stock issued (in shares) 441,009        
Assumed debt $ 1,771        
Acquisition related costs 851        
Fair value of earn-out 25,620 $ 25,620   $ 25,620  
Selling, general and administrative | Stability Biologics, LLC          
Business Acquisition [Line Items]          
Acquisition related costs $ 851        
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) - USD ($)
$ / shares in Units, $ in Thousands
Jan. 13, 2016
Jun. 30, 2016
Dec. 31, 2015
Net assets acquired:      
Goodwill   $ 26,951 $ 4,040
Stability Biologics, LLC      
Business Combination, Consideration Transferred [Abstract]      
Cash paid at closing $ 6,000    
Working capital adjustment (480)    
Common stock issued (441,009 shares valued at $9.07 per share) $ 3,346    
Common stock issued (in shares) 441,009    
Common stock issued, price per share (in dollars per share) $ 9.07    
Assumed debt $ 1,771    
Fair value of earn-out 25,620 $ 25,620  
Total fair value of purchase price 36,257    
Net assets acquired:      
Debt-free working capital 2,179    
Other assets, net 199    
Property, plant and equipment 1,375    
Deferred tax liability (8,268)    
Subtotal (4,515)    
Subtotal 17,860    
Goodwill 22,912    
Total Assets Purchased 36,257    
Cash 140    
Prepaid Expenses and other current assets 100    
Accounts receivable 2,001    
Federal and state taxes receivable 28    
Inventory 8,725    
Accounts payable and accrued expenses (8,815)    
Debt-free working capital 2,179    
Current portion of long term debt (194)    
Net working capital 408    
Other long term assets 199    
Long-term debt | Stability Biologics, LLC      
Net assets acquired:      
Long-term debt (560)    
Line of credit | Stability Biologics, LLC      
Net assets acquired:      
Long-term debt (932)    
Shareholder loan | Stability Biologics, LLC      
Net assets acquired:      
Long-term debt (85)    
Trade names and trademarks | Stability Biologics, LLC      
Net assets acquired:      
Indefinite-lived intangible assets 830    
Customer relationships | Stability Biologics, LLC      
Net assets acquired:      
Finite-Lived intangibles assets 6,090    
Patents and know-how | Stability Biologics, LLC      
Net assets acquired:      
Finite-Lived intangibles assets 9,170    
Non compete agreements | Stability Biologics, LLC      
Net assets acquired:      
Finite-Lived intangibles assets 1,080    
Licenses and permits | Stability Biologics, LLC      
Net assets acquired:      
Finite-Lived intangibles assets $ 690    
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) - Stability Biologics, LLC
Jan. 13, 2016
Customer relationships  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 12 years
Patents and know-how  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 20 years
Non compete agreements  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 4 years
Licenses and permits  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 2 years
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. - Pro Forma Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Business Combinations [Abstract]        
Revenue $ 57,342 $ 50,492 $ 111,258 $ 96,413
Net income $ 2,057 $ 4,919 $ 3,668 $ 7,975
Income per share, fully diluted (in dollars per share) $ 0.02 $ 0.04 $ 0.03 $ 0.07
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Short Term Investments (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Investment [Line Items]    
Short term investments $ 0 $ 3,000
Certificates of Deposit    
Investment [Line Items]    
Short term investments   $ 3,000
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 1,154 $ 602
Work in process 5,888 3,850
Finished goods 11,945 3,405
Inventory, gross 18,987 7,857
Reserve for obsolescence (1,780) (397)
Inventory, net $ 17,207 $ 7,460
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 19,777 $ 14,454
Less accumulated depreciation (6,728) (4,979)
Property and equipment, net 13,049 9,475
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,245 2,684
Lab and clean room equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 8,196 4,564
Furniture and office equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 6,167 4,577
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 2,169 $ 2,629
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation $ 13,049   $ 13,049   $ 9,475
Other liabilities $ 934   $ 934   $ 1,148
Capital leases interest rate effective percentage, minimum 3.00%   3.00%    
Capital leases interest rate effective percentage, maximum 12.00%   12.00%    
Depreciation $ 821 $ 422 $ 1,555 $ 776  
Assets Held under Capital Leases          
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation 427   427    
Other liabilities 72   72    
Leasehold Improvements Paid by Others          
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation $ 1,000   $ 1,000    
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) - USD ($)
 6 Months Ended
Jan. 29, 2007
Jun. 30, 2016
Jan. 13, 2016
Dec. 31, 2015
Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]          
Total   $ 33,815,000   $ 15,627,000  
Less Accumulated amortization and impairment charges   (6,122,000)   (4,864,000)  
Net   27,693,000   10,763,000  
Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Fair value of earn-out   $ 25,620,000 $ 25,620,000    
Licenses          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives (in years)   7 years      
Gross carrying value   $ 1,699,000   1,009,000  
Licenses | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value     690,000    
Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.          
Finite-Lived Intangible Assets [Line Items]          
Acquisition price $ 996,000        
Maximum time of approval (in days) 30 days        
Fair value of earn-out $ 200,000        
Contingent royalty to be paid to licensor 3.00%        
Annual royalty payment, minimum $ 50,000        
Licenses | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         $ 13,000
Patents and know-how          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives (in years)   19 years      
Gross carrying value   $ 17,176,000   8,001,000  
Patents and know-how | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value     9,170,000    
Patents and know-how | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         7,690,000
Finite-Lived Intangible Assets, Costs   $ 4,000      
Customer & supplier relationships          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives (in years)   13 years      
Gross carrying value   $ 9,851,000   3,761,000  
Customer & supplier relationships | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value     6,090,000    
Customer & supplier relationships | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         3,761,000
Non compete agreements          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives (in years)   4 years      
Gross carrying value   $ 1,080,000   0  
Non compete agreements | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value     1,080,000    
Tradenames & trademarks          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   1,838,000   1,008,000  
Tradenames & trademarks | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived     $ 830,000    
Tradenames & trademarks | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived         1,008,000
In process research & development          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   25,000   25,000  
In process research & development | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived         $ 25,000
Patents in process          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   $ 2,146,000   $ 1,823,000  
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details)
$ in Thousands
Jun. 30, 2016
USD ($)
Estimated future amortization expense [Abstract]  
2016 $ 1,259
2017 2,427
2018 2,072
2019 2,072
2020 1,802
Thereafter 16,223
Net book value $ 25,855
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of intangible assets $ 447 $ 233 $ 1,257 $ 465
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Credit Facility (Details) - Credit Agreement - Revolving Credit Facility - USD ($)
Oct. 12, 2015
Jun. 30, 2016
Debt Instrument [Line Items]    
Maximum borrowing capacity (up to) $ 50,000,000  
Uncommitted incremental facility (up to) 35,000,000  
Debt issuance costs $ 500,000  
Debt term 3 years  
Outstanding line of credit   $ 0
Minimum | London Interbank Offered Rate (LIBOR)    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.50%  
Maximum | London Interbank Offered Rate (LIBOR)    
Debt Instrument [Line Items]    
Basis spread on variable rate 2.25%  
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Computation of basic and diluted net loss per share [Abstract]        
Net income $ 1,975 $ 5,430 $ 3,172 $ 9,517
Denominator for basic earnings per share - weighted average shares (in shares) 106,191,932 106,211,120 105,873,727 106,013,752
Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares) 5,956,483 7,975,209 6,221,324 7,878,335
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) 112,148,415 114,186,329 112,095,051 113,892,087
Income (loss) per common share - basic (in dollars per share) $ 0.02 $ 0.05 $ 0.03 $ 0.09
Income (loss) per common share - diluted (in dollars per share) $ 0.02 $ 0.05 $ 0.03 $ 0.08
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 5,956,483 7,975,209 6,221,324 7,878,335
Outstanding Stock Options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 5,644,128 7,411,271 5,805,870 7,393,698
Outstanding Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 0 37,909 0 37,708
Restricted Stock Awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 312,355 526,029 415,454 446,929
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity - Stock Incentive Plans (Details)
 6 Months Ended
Jun. 30, 2016
USD ($)
plan
$ / shares
shares
Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of share-based compensation plans | plan 4  
Number of shares [Roll forward]    
Outstanding, beginning of period (in shares) | shares 14,019,629  
Granted (in shares) | shares 0  
Exercised (in shares) | shares (804,041)  
Unvested options forfeited (in shares) | shares (79,810)  
Vested options expired (in shares) | shares (29,191)  
Outstanding, end of period (in shares) | shares 13,106,587  
Vested at end of period (in shares) | shares 11,710,880  
Exercisable options, vested and expected to vest (in shares) | shares 13,047,941  
Weighted-Average Exercise Price [Roll forward]    
Outstanding, weighted average exercise price, beginning of period (in dollars per share) $ 3.62  
Granted, weighted average exercise price (in dollars per share) 0.00  
Exercised, weighted average exercise price (in dollars per share) 2.51  
Unvested options forfeited, weighted-average exercise price (in dollars per share) 6.44  
Vested options expired, weighted-average exercise price (in dollars per share) 6.44  
Outstanding, weighted average exercise price, end of period (in dollars per share) 3.67  
Vested at end of period, weighted average exercise price (in dollars per share) 3.27  
Vested and expected to vest, weighted average exercise price (in dollars per share) $ 3.66  
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 6 years  
Vested at end of period, weighted average remaining contractual term (in years) 5 years 9 months 18 days  
Vested and expected to vest, weighted average remaining contractual term (in years) 6 years  
Outstanding, aggregate intrinsic value | $ $ 56,844,050  
Vested at end of period, aggregate intrinsic value | $ 55,362,178  
Vested or expected to vest, aggregate intrinsic value | $ 56,809,041  
Exercised options, intrinsic value | $ $ 4,937,922  
Number of outstanding options (in shares) | shares 13,106,587  
Outstanding Options, weighted average remaining contractual term (in years) 6 years  
Outstanding Options, weighted average exercise price (in dollars per share) $ 3.67  
Number of exercisable options (in shares) | shares 11,730,880  
Exercisable Options, weighted average exercise price (in dollars per share) $ 3.27  
Total unrecognized compensation expense | $ $ 3,283,152  
Fair value options valuation assumptions [Abstract]    
Expected volatility Minimum   54.40%
Expected volatility Maximum   58.10%
Expected life (in years)   6 years
Expected dividend yield   0.00%
Risk-free interest rate Minimum   1.51%
Risk-free interest rate Maximum   1.68%
$0.50 - $0.76    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 2 years 10 months 24 days  
Exercise Price Range, lower range limit (in dollars per share) $ 0.50  
Exercise Price Range, upper range limit (in dollars per share) $ 0.76  
Number of outstanding options (in shares) | shares 441,429  
Outstanding Options, weighted average remaining contractual term (in years) 2 years 10 months 24 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 0.72  
Number of exercisable options (in shares) | shares 441,429  
Exercisable Options, weighted average exercise price (in dollars per share) $ 0.72  
$0.87 - $1.35    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 5 years 2 months 12 days  
Exercise Price Range, lower range limit (in dollars per share) $ 0.87  
Exercise Price Range, upper range limit (in dollars per share) $ 1.35  
Number of outstanding options (in shares) | shares 4,420,470  
Outstanding Options, weighted average remaining contractual term (in years) 5 years 2 months 12 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 1.19  
Number of exercisable options (in shares) | shares 4,420,470  
Exercisable Options, weighted average exercise price (in dollars per share) $ 1.19  
$1.40 - $2.45    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 4 years 4 months 24 days  
Exercise Price Range, lower range limit (in dollars per share) $ 1.40  
Exercise Price Range, upper range limit (in dollars per share) $ 2.45  
Number of outstanding options (in shares) | shares 1,458,424  
Outstanding Options, weighted average remaining contractual term (in years) 4 years 4 months 24 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 1.92  
Number of exercisable options (in shares) | shares 1,458,424  
Exercisable Options, weighted average exercise price (in dollars per share) $ 1.92  
$2.66 - $3.99    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 6 years 3 months 18 days  
Exercise Price Range, lower range limit (in dollars per share) $ 2.66  
Exercise Price Range, upper range limit (in dollars per share) $ 3.99  
Number of outstanding options (in shares) | shares 889,430  
Outstanding Options, weighted average remaining contractual term (in years) 6 years 3 months 18 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 3.06  
Number of exercisable options (in shares) | shares 889,430  
Exercisable Options, weighted average exercise price (in dollars per share) $ 3.06  
$4.19 - $6.38    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 6 years 10 months 24 days  
Exercise Price Range, lower range limit (in dollars per share) $ 4.19  
Exercise Price Range, upper range limit (in dollars per share) $ 6.38  
Number of outstanding options (in shares) | shares 3,310,253  
Outstanding Options, weighted average remaining contractual term (in years) 6 years 10 months 24 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 5.36  
Number of exercisable options (in shares) | shares 2,898,133  
Exercisable Options, weighted average exercise price (in dollars per share) $ 5.28  
$6.45 - $9.78    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 7 years 7 months 6 days  
Exercise Price Range, lower range limit (in dollars per share) $ 6.45  
Exercise Price Range, upper range limit (in dollars per share) $ 9.78  
Number of outstanding options (in shares) | shares 2,479,415  
Outstanding Options, weighted average remaining contractual term (in years) 7 years 7 months 6 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 7.29  
Number of exercisable options (in shares) | shares 1,586,502  
Exercisable Options, weighted average exercise price (in dollars per share) $ 7.23  
$9.90- $10.99    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 8 years 4 months 24 days  
Exercise Price Range, lower range limit (in dollars per share) $ 9.90  
Exercise Price Range, upper range limit (in dollars per share) $ 10.99  
Number of outstanding options (in shares) | shares 107,166  
Outstanding Options, weighted average remaining contractual term (in years) 8 years 4 months 24 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 10.43  
Number of exercisable options (in shares) | shares 36,492  
Exercisable Options, weighted average exercise price (in dollars per share) $ 10.44  
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity - Restricted Stock Awards (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Dec. 31, 2015
Share-based Compensation [Abstract]            
Share-based compensation expense $ 4,503,000 $ 4,255,000 $ 9,124,000 $ 8,186,000    
Cost of sales            
Share-based Compensation [Abstract]            
Share-based compensation expense 95,000 90,000 190,000 184,000    
Research and development            
Share-based Compensation [Abstract]            
Share-based compensation expense 155,000 203,000 360,000 389,000    
Selling, general and administrative            
Share-based Compensation [Abstract]            
Share-based compensation expense $ 4,253,000 $ 3,962,000 $ 8,574,000 $ 7,613,000    
Restricted Stock Awards            
Number of Shares            
Unvested, Beginning Balance (in shares)     2,613,267      
Granted (in shares)     2,014,838      
Vested (in shares)     (825,595)      
Forfeited (in shares)     (102,230)      
Unvested, Ending Balance (in shares) 3,700,280   3,700,280      
Weighted- Average Grant Date Fair Value            
Unvested, Beginning Balance (in dollars per share) $ 8.66   $ 8.66   $ 8.66 $ 9.14
Granted (in dollars per share)     8.04      
Vested (in dollars per share)     8.63      
Forfeited (in dollars per share)     8.85      
Unvested, Ending Balance (in dollars per share) $ 8.66   $ 8.66      
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock         $ 24,939,716  
Expenses expected to be recognized over a weighted-average period (in years)     2 years 1 month 6 days      
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity - Treasury Stock (Details) - USD ($)
 6 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Dec. 31, 2014
May 12, 2014
Equity [Abstract]        
Authorized share amount for repurchase (up to)   $ 60,000,000 $ 20,000,000 $ 10,000,000
Stock repurchase (in shares) 415,252      
Shares repurchased, value $ 3,518,000      
Brokerage commissions 12,000      
Remaining authorizations under the repurchase program $ 10,756,000      
Shares reissued from the treasury (in shares) 2,599,377      
Shares reissued from the treasury, value $ 21,334,000      
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2016
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2016
Dec. 31, 2015
Income Tax Contingency [Line Items]          
Effective tax rate   34.70% 3.70%    
Effective income tax rate increase (decrease), amount $ 350        
Effective income tax rate increase (decrease), percent   31.00%      
Decrease in valuation allowance         $ 15,400
Forecast          
Income Tax Contingency [Line Items]          
Effective tax rate       42.20%  
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]    
Cash paid for interest $ 76 $ 29
Income taxes paid 631 874
Stock issuance of 441,009 shares in connection with acquisition $ 3,346 0
Shares issued in conjunction with acquisition (in shares) 441,009  
Retirement of fixed assets $ 0 308
Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively $ 173 $ 108
Shares issued for services performed (in shares) 20,406 11,321
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.5.0.2
Contractual Commitments and Contingencies - Narrative (Details)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2016
USD ($)
claim
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
claim
Jun. 30, 2015
USD ($)
Dec. 31, 2015
Dec. 30, 2015
term
Dec. 22, 2015
term
Oct. 02, 2015
term
Aug. 18, 2015
claim
Jul. 10, 2015
claim
Jun. 29, 2015
claim
Loss Contingencies [Line Items]                      
Lease expiration period (in years)     8 years                
Rent expense | $ $ 436 $ 310 $ 859 $ 593              
Pending Litigation                      
Loss Contingencies [Line Items]                      
Number of patent challenged grounds 4   4                
Pending Litigation | Liventa Action                      
Loss Contingencies [Line Items]                      
Number of pending disputed claim terms | term           1 30        
Pending Litigation | Bone Bank Action                      
Loss Contingencies [Line Items]                      
Number of patent challenged grounds                   5 7
Number of pending disputed claim terms | term               1      
Opinion allowing a review of patent                   2  
Pending Litigation | Liventa Action, 701 Patent                      
Loss Contingencies [Line Items]                      
Number of patent challenged grounds                 6    
Pending Litigation | Liventa Action, 437 Patent                      
Loss Contingencies [Line Items]                      
Number of patent challenged grounds                 7    
Opinion allowing a review of patent                 1    
Sales Revenue, Net | Product Concentration Risk                      
Loss Contingencies [Line Items]                      
Percentage of revenue         12.00%            
Standby Letters of Credit                      
Loss Contingencies [Line Items]                      
Standby letters of credit | $ $ 118   $ 118                
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.5.0.2
Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details)
$ in Thousands
Jun. 30, 2016
USD ($)
Estimated annual lease, royalty, and employment agreement expenses [Abstract]  
2017 $ 3,310
2018 3,128
2019 2,052
2020 1,366
Thereafter 644
Total Contractual commitments $ 10,500
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.5.0.2
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Allowance for doubtful accounts        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period $ 3,872 $ 2,010 $ 3,270 $ 1,750
Additions charged to Expense or Revenue 233 500 835 760
Deductions and write-offs (19) (6) (19) (6)
Balance at End of Period 4,086 2,504 4,086 2,504
Allowance for product returns        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period 1,708 944 1,262 841
Additions charged to Expense or Revenue 2,106 734 3,467 1,443
Deductions and write-offs (1,623) (648) (2,538) (1,254)
Balance at End of Period 2,191 1,030 2,191 1,030
Allowance for obsolescence        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period 604 552 397 527
Additions charged to Expense or Revenue 1,335 90 1,570 221
Deductions and write-offs (159) (89) (187) (195)
Balance at End of Period $ 1,780 $ 553 $ 1,780 $ 553
EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 170 286 1 false 58 0 false 8 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://mimedx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101100 - Disclosure - Basis of Presentation Sheet http://mimedx.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 2102100 - Disclosure - Significant Accounting Policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Liquidity and Management's Plans Sheet http://mimedx.com/role/LiquidityAndManagementsPlans Liquidity and Management's Plans Notes 9 false false R10.htm 2104100 - Disclosure - Acquisition of Stability Inc. Sheet http://mimedx.com/role/AcquisitionOfStabilityInc Acquisition of Stability Inc. Notes 10 false false R11.htm 2105100 - Disclosure - Short Term Investments Sheet http://mimedx.com/role/ShortTermInvestments Short Term Investments Notes 11 false false R12.htm 2106100 - Disclosure - Inventories Sheet http://mimedx.com/role/Inventories Inventories Notes 12 false false R13.htm 2107100 - Disclosure - Property and Equipment Sheet http://mimedx.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 2108100 - Disclosure - Intangible Assets and Royalty Agreement Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreement Intangible Assets and Royalty Agreement Notes 14 false false R15.htm 2109100 - Disclosure - Credit Facility Sheet http://mimedx.com/role/CreditFacility Credit Facility Notes 15 false false R16.htm 2110100 - Disclosure - Net Income (Loss) Per Share Sheet http://mimedx.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 16 false false R17.htm 2111100 - Disclosure - Equity Sheet http://mimedx.com/role/Equity Equity Notes 17 false false R18.htm 2112100 - Disclosure - Income taxes Sheet http://mimedx.com/role/IncomeTaxes Income taxes Notes 18 false false R19.htm 2114100 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities Supplemental disclosure of cash flow and non-cash investing and financing activities Notes 19 false false R20.htm 2115100 - Disclosure - Contractual Commitments and Contingencies Sheet http://mimedx.com/role/ContractualCommitmentsAndContingencies Contractual Commitments and Contingencies Notes 20 false false R21.htm 2116100 - Disclosure - Subsequent Events Sheet http://mimedx.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 2117100 - Schedule - Schedule II - Valuation and Qualifying Accounts Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Uncategorized 22 false false R23.htm 2202201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mimedx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Uncategorized 23 false false R24.htm 2304301 - Disclosure - Acquisition of Stability Inc. (Tables) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncTables Acquisition of Stability Inc. (Tables) Uncategorized 24 false false R25.htm 2306301 - Disclosure - Inventories (Tables) Sheet http://mimedx.com/role/InventoriesTables Inventories (Tables) Uncategorized 25 false false R26.htm 2307301 - Disclosure - Property and Equipment (Tables) Sheet http://mimedx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Uncategorized 26 false false R27.htm 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementTables Intangible Assets and Royalty Agreement (Tables) Uncategorized 27 false false R28.htm 2310301 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://mimedx.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Uncategorized 28 false false R29.htm 2311301 - Disclosure - Equity (Tables) Sheet http://mimedx.com/role/EquityTables Equity (Tables) Uncategorized 29 false false R30.htm 2314301 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) Uncategorized 30 false false R31.htm 2315301 - Disclosure - Contractual Commitments and Contingencies (Tables) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesTables Contractual Commitments and Contingencies (Tables) Uncategorized 31 false false R32.htm 2401401 - Disclosure - Basis of Presentation (Details) Sheet http://mimedx.com/role/BasisOfPresentationDetails Basis of Presentation (Details) Uncategorized 32 false false R33.htm 2402402 - Disclosure - Significant Accounting Policies (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Uncategorized 33 false false R34.htm 2403401 - Disclosure - Liquidity and Management's Plans (Details) Sheet http://mimedx.com/role/LiquidityAndManagementsPlansDetails Liquidity and Management's Plans (Details) Uncategorized 34 false false R35.htm 2404402 - Disclosure - Acquisition of Stability Inc. - Narrative (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncNarrativeDetails Acquisition of Stability Inc. - Narrative (Details) Uncategorized 35 false false R36.htm 2404403 - Disclosure - Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncPreliminarilyAllocationOfPurchasePriceDetails Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) Uncategorized 36 false false R37.htm 2404404 - Disclosure - Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncIntangibleAssetsAcquiredAsPartOfAcquisitionDetails Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) Uncategorized 37 false false R38.htm 2404405 - Disclosure - Acquisition of Stability Inc. - Pro Forma Information (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncProFormaInformationDetails Acquisition of Stability Inc. - Pro Forma Information (Details) Uncategorized 38 false false R39.htm 2405401 - Disclosure - Short Term Investments (Details) Sheet http://mimedx.com/role/ShortTermInvestmentsDetails Short Term Investments (Details) Uncategorized 39 false false R40.htm 2406402 - Disclosure - Inventories (Details) Sheet http://mimedx.com/role/InventoriesDetails Inventories (Details) Uncategorized 40 false false R41.htm 2407402 - Disclosure - Property and Equipment (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Uncategorized 41 false false R42.htm 2407403 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Uncategorized 42 false false R43.htm 2408402 - Disclosure - Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementSummaryOfIntangibleAssetsDetails Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) Uncategorized 43 false false R44.htm 2408403 - Disclosure - Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) Uncategorized 44 false false R45.htm 2408404 - Disclosure - Intangible Assets and Royalty Agreement - Narrative (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementNarrativeDetails Intangible Assets and Royalty Agreement - Narrative (Details) Uncategorized 45 false false R46.htm 2409401 - Disclosure - Credit Facility (Details) Sheet http://mimedx.com/role/CreditFacilityDetails Credit Facility (Details) Uncategorized 46 false false R47.htm 2410402 - Disclosure - Net Income (Loss) Per Share (Details) Sheet http://mimedx.com/role/NetIncomeLossPerShareDetails Net Income (Loss) Per Share (Details) Uncategorized 47 false false R48.htm 2411402 - Disclosure - Equity - Stock Incentive Plans (Details) Sheet http://mimedx.com/role/EquityStockIncentivePlansDetails Equity - Stock Incentive Plans (Details) Uncategorized 48 false false R49.htm 2411403 - Disclosure - Equity - Restricted Stock Awards (Details) Sheet http://mimedx.com/role/EquityRestrictedStockAwardsDetails Equity - Restricted Stock Awards (Details) Uncategorized 49 false false R50.htm 2411404 - Disclosure - Equity - Treasury Stock (Details) Sheet http://mimedx.com/role/EquityTreasuryStockDetails Equity - Treasury Stock (Details) Uncategorized 50 false false R51.htm 2412401 - Disclosure - Income taxes (Details) Sheet http://mimedx.com/role/IncomeTaxesDetails Income taxes (Details) Uncategorized 51 false false R52.htm 2414402 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) Uncategorized 52 false false R53.htm 2415402 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails Contractual Commitments and Contingencies - Narrative (Details) Uncategorized 53 false false R54.htm 2415403 - Disclosure - Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesEstimatedAnnualLeasePaymentsDetails Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) Uncategorized 54 false false R55.htm 2417401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Uncategorized 55 false false All Reports Book All Reports mdxg-20160630.xml mdxg-20160630.xsd mdxg-20160630_cal.xml mdxg-20160630_def.xml mdxg-20160630_lab.xml mdxg-20160630_pre.xml true true ZIP 76 0001376339-16-000203-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-16-000203-xbrl.zip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�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